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ABSTRACT 
 
 
 Background: Persons with a severe mental illness (SMI) prematurely lose up to 
25 years of life when compared to the general population. This patient population has 
increased morbidity and mortality due to higher than normal rates of obesity, 
hypertension, diabetes, and cardiovascular disease. Treatment of SMI often includes the 
use of atypical antipsychotic (AA) medication which has been associated with the 
development of cardiometabolic illnesses. In response to the higher rates of co-morbid, 
chronic physical illness, monitoring guidelines for cardiometabolic illness have been 
published. Despite these guidelines, screening rates for cardiometabolic illness in this 
population remain low. Neither community mental health nor primary care systems 
address the physical health concerns of persons with a severe mental illness, thus 
widening the quality gap for this at-risk, vulnerable population. The Chronic Care Model 
provides a systems framework for addressing the wide range of health needs for 
chronically ill populations and has successfully been used in improving the quality of 
care for persons with chronic physical health conditions. Few published studies have used 
the Chronic Care Model as a framework to guide improving the quality of care for 
persons with a SMI.  
 
 Objective: The purpose of this study was to better understand how the delivery 
system design of a community mental health center affects quality outcomes for persons 
with a SMI treated on an AA medication that are at high risk for developing 
cardiometabolic illness.  
 
 Methods: This cross-sectional study used baseline patient health data of persons 
with a SMI to analyze cardiometabolic screening rates, based on the American Diabetes 
Association (ADA), American Psychiatric Association (APA), Association of Clinical 
Endocrinologists, and North American Association for the Study of Obesity second 
generation antipsychotic monitoring guideline. The guideline included history of 
cardiovascular disease and biologic monitoring at baseline, 12 weeks, and both baseline 
and 12 weeks. This retrospective study used existing data from an electronic health 
record. A member of the clinic data team electronically extracted study demographic 
variables. All other study variables were manually extracted by the study investigator. 
The theoretical basis for this study was supported by the Care Model, an adapted version 
of the Chronic Care Model.  
 
 Results: The study sample consisted of 190 patients. The mean patient age was 
37.13 years with a SD ± 11.7 years and a range of 19 - 70 years. The majority of patients 
were men (58.4%) and most patients were single (90.5%). More than one-half of the 
patients (53.7%) represented a minority race, though most patients were not Hispanic 
(95.3%). Most patients were not currently employed (88.9%) and nearly one-half of the 
patients lived below the federal poverty guidelines (47.4%). Ninety percent of the 
patients were enrolled in the Medicare or State Medical Assistance program. More 
patients in the study were diagnosed with a mood disorder (72.1%) than a thought 
disorder (27.9%). Most patients (61.6%) did not schedule their baseline or follow-up 
vi 
visit, but rather “walked” into the clinic without prior notice. The average number of 
visits during the initial treatment phase was 3.7 ± 1.4 and more than one-third of patients 
had the same provider at baseline and follow-up (36.3%).  
  
 No patients received all recommended screening measures per the ADA and APA 
monitoring guideline. Biological measures (excluding history of cardiovascular disease) 
were evaluated for ten patients at baseline, three patients at follow-up and one patient at 
both baseline and follow-up. At baseline, rates for each screening measure were as 
follows: weight or BMI (64.2%), blood pressure (62.1%), fasting plasma glucose or 
hemoglobin A1c (27.9%), fasting lipid profile (8.4%) and family or personal history of 
cardiovascular disease (34.7%). At follow-up, rates of each cardiometabolic screening 
measure were as follows: weight or BMI (63.2%), blood pressure (61.6%), fasting plasma 
glucose or hemoglobin A1c (13.2%), fasting lipid profile (9.5%). Summaries of the 
unadjusted (r) and adjusted (beta) associations between combined delivery system design 
candidate variables and each of the quality outcome variables at baseline revealed 
associations between being a current smoker (r = .15, p = .041), having a clinic primary 
care provider (r = .21, p = .003), being a walk-in at baseline (r = .14, p - .048), and the 
number of screening measures. At follow-up, no statistically significant associations were 
observed.  
  
Conclusion: Data suggest that the delivery system design of a community mental 
health center inadequately addresses screening for cardiometabolic symptoms of persons 
with SMI. Findings show that adherence to the full panel of ADA and APA 
recommended cardiometabolic screening measures for persons treated on an AA 
medication is abysmal. Even rates of common screening measures, such as blood 
pressure, are poor. The Care Model was a useful theoretical framework to guide the 
study. Results of the study indicate that SMI patients may interact with the health care 
system differently than patients with chronic medical conditions. It is feasible that the 
high rate of unscheduled visits, or “walk-in” visits and number of different providers 
caring for patients during the initial treatment phase contributes to poor quality care. 
Subsequent recommendations include developing an intervention study to evaluate 
quality outcomes using a) an integrated care delivery design specifically for SMI patients 
and b) expanding the Care Model components to include the health system organization, 
decision support, self-management support, and clinical information systems. It is 
critically important that care delivery systems for persons with SMI be integrated for 
optimal health outcomes.  
vii 
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CHAPTER 1.    INTRODUCTION 
 
 
Persons with a severe mental illness (SMI) prematurely lose 10 – 25 years of life 
as compared to the general population (Miller, Paschall, & Svendsen, 2006; Richardson 
et al., 2005). Cardiovascular disease is the most common cause of excessive mortality in 
this population (Richardson et al.). Causes of cardiovascular disease and premature death, 
such as hypertension, obesity, and diabetes, have been associated with use of atypical 
antipsychotic (AA) medication (Amiel, Mangurian, Ganguli, & Newcomer, 2008). 
Though it has been eight years since recommendations for cardiometabolic screening for 
persons treated on AA medication were first published, patients continue to go 
unscreened.  
 
This chapter describes (1) critical issues in quality care for SMI patients, (2) the 
significance of the Care Model to ensure quality care delivery, and (3) the importance of 
following practice standards to improve health outcomes for all patients with a SMI. A 
broad overview of the problem will be presented, followed by the purpose of the study, 
research questions, the theoretical framework, operational definitions, and the 
significance of the study. 
 
 
Statement of the Problem 
 
Grave disparities in access to mental and physical health care exist for persons 
with a SMI creating an urgent need to integrate these two systems of care for this 
population (U.S. Department of Health and Human Services, 1999). One 
recommendation from The Institute of Medicine (IOM) involves focusing on quality of 
care to improve health outcomes for persons with a mental illness (2001). As a result, 
integration of physical and mental health care is a health care priority for the 21
st
 century. 
 
Access to health care in the United States (U.S.) is often difficult to obtain and 
delivered by complex and fragmented systems, which leads to suboptimal patient 
outcomes (Cebul, Rebitzer, Taylor, & Votruba, 2008). Historically, health care systems 
focused on treatment of acute and infectious diseases, as these were the leading causes of 
disability and death in the U.S. (Glasgow, Orleans, & Wagner, 2001). Currently, chronic 
illness affects almost one out of every two Americans (Von Korff, Gruman, Schaefer, 
Curry, & Wagner, 1997) or about one hundred million persons, half of whom have more 
than one chronic illness (Bodenheimer & Grumbach, 2007). This number is expected to 
increase at a rapid rate given the number of aging persons in the U.S. (Wagner, Austin et 
al., 2001). The cause of or increase in morbidity from chronic illness is often due to 
preventable lifestyle related behaviors (Hung et al., 2007).  Persons who have a SMI have 
additional disease related and psychosocial barriers to achieving healthy lifestyle 
behaviors and therefore, interventions are needed to target this vulnerable population. A 
charge for healthcare delivery systems in the 21
st
 century is to prevent and manage 
chronic disease (Glasgow et al., 2001). The Institute of Medicine (2001) identified a call 
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to action to improve the healthcare delivery system and shift care from a focus on acute 
to chronic conditions. 
 
Chronic care management of persons with a SMI requires understanding that a 
diagnosis of a severe mental illness is an independent risk factor for the development of 
cardiovascular disease.  Persons with schizophrenia and bipolar disorder have an 
increased risk for diabetes and obesity (Daumit, Pratt, Crum, Powe, & Ford, 2002) and 
develop cardiovascular disease at rates twice that of the general population (Hansen, 
Jacobsen, & Arnesen, 2001; Morden, Mistler, Weeks, & Bartels, 2009; Saha, Chant, & 
McGrath, 2007). This population has higher morbidity and mortality rates when 
compared to the general population (Daumit et al., 2002).  In addition to unknown 
independent risk factors of cardiovascular disease, persons with a SMI have modifiable 
risk factors. For example, many individuals with a SMI have a low income, are on 
disability, and have limited access to healthy foods, resulting in higher rates of high-fat 
food intake. Additionally, persons with a SMI often smoke cigarettes, smoking at rates 
twice as high as the general population (Daumit et al., 2002; Lasser et al., 2000). For 
persons with schizophrenia, there is evidence of a vulnerability to nicotine addiction. This 
interaction makes quitting more difficult since it is suggested that nicotine can improve 
attention in this population (McEvoy & Allen, 2002). Unfortunately, though the risks of 
co-morbid physical health in persons with a SMI are well documented, care is typically 
not focused on chronic disease management of both the mental and physical illness. 
 
Neither traditional community mental health nor primary care systems address the 
physical health concerns of persons with SMI, further increasing fragmentation and 
widening the quality gap for this at-risk, vulnerable population. Disparities in primary 
care exist for persons with SMI. Not only has treatment failed to achieve better physical 
health outcomes for persons with SMI, their care has been noted to be less than optimal. 
Persons with a SMI who present to a primary care provider are often under treated or not 
treated at all. Despite receiving more time with the provider during office visits, SMI 
patients do not typically receive screening and preventive services (Daumit et al., 2002).  
Subsequently, this population is developing chronic multimorbid health problems at 
alarming rates, requiring an immediate reform to the systems of care (Daumit et al., 
2002). 
 
Over the last 20 years there has been a national emphasis on identifying and 
treating mental illness which has resulted in new approaches to the treatment of mental 
illness. The U.S. declared the 1990’s the decade of the brain. During this time, federal 
dollars were available to study treatment approaches and the brain (Frese, Stanley, Kress, 
& Vogel Scibilia, 2001). Additionally, in 1999 the U.S. Surgeon General published the 
first ever report on mental health (U.S. Department of Health and Human Services, 
1999). This report cited that mental health is a public health problem that must be 
addressed by the nation and that mental health is vital to physical health. Following these 
two seminal events, in 2002 the President of the United States established the New 
Freedom Commission on Mental Health to analyze both public and private mental health 
systems. The New Freedom Commission on Mental Health report identified fragmented 
care, less than optimal outcomes, and high costs to treat SMI (Hogan, 2003). It was 
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during this time that many advances were made for the treatment of persons with a SMI. 
These events have advanced a movement to address the mental and physical treatment of 
persons with a SMI. 
 
Addressing mental and physical healthcare treatment in a systematic way requires 
a common definition of SMI; however, persons with a SMI have been defined differently 
by various authors and an international agreement on how to define a SMI is lacking 
(Ruggeri, Leese, Thornicroft, Bisoffi, & Tansella, 2000). Goldman, Gattozi, and Taube 
(1981) state that deinstitutionalization of mentally ill patients created a necessity to 
develop a consensus for classifying persons with a SMI.  During this time, many 
individuals were faced with living in the community; therefore, outpatient services for the 
treatment of persons with a SMI were developed. Various authors use different criteria to 
define a SMI and based on the inclusion criteria, the prevalence of a SMI can range from 
4% to 88% of persons with a severe mental illness (Schinnar, Rothbard, Kanter, & Jung, 
1990). The National Institute of Mental Health (1987) has a broad and widely accepted 
definition of SMI which includes various illnesses with identified timeframes. However, 
Narrow and colleagues (2000) have a more specific definition and cite just over 3% of 
adults have a SMI in the US with 1.5% having schizophrenia, 1% having bipolar disorder 
and 1% with treatment refractory depression. Various Medicaid payments are based on a 
global assessment of the patient, which includes The Diagnostic and Statistical Manual 
IV- Text Revision (DSM IV-TR) Axis I-V diagnosis and other functional rating scales. 
For purposes of this study, SMI is conceptualized as conditions within the DSM IV TR 
Axis I diagnosis: Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not 
Otherwise Specified, Bipolar Disorder or Major Depressive Disorder, Recurrent. 
Evaluating healthcare outcomes also requires an explicit understanding of how the course 
of illness in an affected population impacts how an individual engages with the 
healthcare system. Through a better understanding the illness trajectory  for persons with 
SMI, models can be developed to predict the course of treatment that will enable 
providers to proactively plan care and achieve the best possible outcomes for this 
vulnerable population. 
 
Persons with a SMI are considered a vulnerable population as are immigrants 
(persons who live in a country other than their country of origin). Immigrants can be U.S. 
born or foreign born. This patient population is much like persons with a SMI, both 
populations often have lower socioeconomic status, which includes factors such as  
income, education, occupation and these factors have been linked to mental health 
problems (U.S. Department of Mental Health and Human Services, 1999).  
 
Immigrants are a vulnerable population who are at risk for poor physical and 
mental health (Derose, Escarce, & Lurie, 2007). In 2009 there were approximately 
38.5million foreign born immigrants in the U.S. which represents about 1 in 8 residents 
(U.S. Census Bureau, 2010). Within the U.S., immigrants are a heterogeneous population 
with the highest percent coming from Latin America (53%) followed by Asia (28%) and 
Africa (4%) (U.S. Census Bureau). The upper Midwest region of the U.S. has less than 
6% immigrant population in each state, with the exception of Illinois with 10-15% and 
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Minnesota with 6-10% of the state population being foreign born immigrants (U.S. 
Census Bureau). 
 
The length of time an immigrant resides in the U.S. is associated with higher rates 
of assimilation and acculturation. One study shows that the longer immigrants live in the 
US and the more acculturated they become and the more their health declines (Derose et 
al., 2007). These authors cite adoption of unhealthy habits, living in high risk  
environments and reduced access to medical services as a source of being at high risk for 
disease.  Access to medical services and disparities in health care quality has also been 
identified by race, ethnicity, socioeconomic status, and language. 
 
In 2000 there were over 281 million persons living in the U.S., 26 million of 
whom were non-English speakers; 9 million were linguistically isolated and 3 million 
spoke no English (U.S. Census Bureau, 2000). Language proficiency and the ability to 
speak English impacts access to health care. A recent national sample found that Spanish-
speaking and black patients are less likely than non-Hispanic white patients to have had a 
mental health visit (Fiscella, Franks, Doescher, & Saver, 2002). Persons with limited 
English proficiency were also found to have fewer physician visits and receive less 
preventive care. Mohanty and colleagues (2005) found that immigrants are reported to 
have lower education, come from lower income levels, and self-report poorer health. 
Immigrants often express health in a cultural context; however, the diagnostic criteria for 
SMI are the same for all populations in the U.S. A recent meta-analysis showed that 
family history was the greatest risk factor for developing schizophrenia; however, foreign 
born migrants with dark skin are at higher risk as compared to controls (Cantor Graae & 
Selten, 2005). 
 
The onset of a SMI occurs in early or middle adulthood, between 20 and 35 years 
of age. This age range is a time when most people are physically healthy and have limited 
contact with the health care system. Individuals with symptoms of a mental illness 
typically present in a primary care system with initial symptoms  but  receive ongoing 
treatment of a mental illness within  the mental health system of care, most often a 
community mental health center (CMHC). This handoff increases fragmentation, creating 
the first of many opportunities for poor quality health care. Subsequently, seamless 
healthcare models focused on both mental and physical health are needed to improve 
outcomes for persons with SMI. 
 
 
Chronic Care Model 
 
The Chronic Care Model (CCM) provides a systems framework for addressing 
the wide range of health needs for chronically ill populations. This model was developed 
by Wagner and colleagues (1998) to address the lack of access to care and the poor 
quality associated with management of persons with chronic illnesses. The Chronic Care 
Model was introduced by Wagner and colleagues, in collaboration with the MacColl 
Institute for Healthcare Innovation after an extensive literature review on best practices 
for chronic illness management. The CCM is a comprehensive framework designed to be 
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a functional blueprint (Glasgow et al., 2001) to help improve patient outcomes through 
six interrelated systems: organization of healthcare, community resources, self-
management support, delivery system design, decision supports, and clinical information 
systems (Coleman, Austin, Brach, & Wagner, 2009). The CCM defines the six broad 
areas that must be considered, but is not prescriptive (Glasgow et al., 2001), an abstract 
theory (Bodenheimer, Lorig, Holman, & Grumbach, 2002) or an explanatory theory 
(Wagner, Glasgow et al., 2001) Rather it is a multidimensional solution (Bodenheimer et 
al., 2002) that will guide practice through the interaction of the six systems to develop 
informed, empowered patients and a prepared proactive practice team that synergistically 
create productive interactions that lead to improved health outcomes. This framework is 
intended to be tailored to various chronic conditions and applied to a variety of care 
settings and populations (Hung et al., 2007; Glasgow et al., 2001). Further, the CCM is a 
framework that can be used to guide changes in health care delivery that enhance health 
outcomes (Piatt et al., 2006).  
 
The CCM has been proposed as a way to integrate mental health care and primary 
care (Mulligan, 2003) and has been adapted to develop a bipolar care model (Kilbourne 
et al., 2008). As an adaptation of the CCM, the Institute for Health Care Improvement 
(ICIC) has proposed an Expanded CCM which widens the community portion of the 
model to include health determinants (Barr et al., 2003). The Care Model (CM) 
incorporates the IOM underpinnings of care that is patient centered, timely and efficient, 
evidence based, and safe and coordinated. It is postulated that because the purpose of the 
Robert Wood Johnson Foundation (RWJF) initiative was to examine the effectiveness of 
the CCM in medical homes, much of the current literature relates to the CCM introduced 
in 1998, rather than an adapted version. The Care Model includes the same six core 
systems as the CCM with the one difference that the CM includes the IOM quality 
underpinning, which leads to an informed, empowered patient and family as opposed to 
the CCM’s informed, activated patient.  
 
Seminal studies of the CCM focused on the interactions of the elements in the 
CCM with the health care system; however, a study by Sperl, Hillen et al. (2004) not only 
acknowledged interactions of the CCM, but also noted that a theoretical case can be made 
to examine individual components of the CCM. Several reasons support the case that 
individual elements of the CCM can be individually evaluated. For example,  health care 
systems are complex. Change within a health care system  is nonlinear with differing 
effects on the parts of the system. Subsequently, individual CCM components may need 
to be tested to detect intervention effectiveness. A second reason is that healthcare 
organizations do not have the resources to implement all aspects of the CCM 
simultaneously. Therefore, individual components of the CCM must be able to be studied 
to generate new knowledge and guide progress. Moreover, several studies have measured 
the impact of specific CCM components, such as self-management (Polonsky et al., 
2003) and the delivery system design (Schmittdiel, Uratsu, Fireman, & Selby, 2009) on 
diabetic outcomes. Findings support the concept that the CCM can be examined by its 
individual components because changes to individual components can improve care 
outcomes (Nutting et al., 2007).     
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Blakely and Dziadosz (2008) note that the CCM has been used in the primary care 
setting for guiding care changes for persons with a SMI; however, few community mental 
health centers are familiar with the CCM. This study indicated that the CCM was 
successful in making practice changes to the structure and function of care for persons 
with a SMI. Kilbourne et al. (2008) also found elements of the CCM used in an adapted 
Bipolar Care Model to be successful in improving outcomes for persons with SMI.  
 
As a highlight of the CCM, Wagner, Austin, and Von Korff (1996) acknowledge 
that the delivery system design is vital to providing quality care to patients. The delivery 
system design is the component of the CCM through which innovations in care delivery 
are implemented. Further, the delivery system design of a health care organization 
represents an opportunity to change the environment in which the care team, patient, and 
visit characteristics interact. While the delivery system design does not directly impact 
health outcomes (Oprea, Braunack, Mayer, Rogers, & Stocks, 2010), the CCM has been 
used to guide evidence based treatment for chronic conditions such as diabetes and 
attention deficit hyperactivity disorder (Nutting et al., 2007; Parchman, Zeber, Romero, 
& Pugh, 2007; Sperl, Hillen et al., 2004; Van Cleave & Leslie, 2008). Elements of the 
delivery system design in the CCM are present in a CMHC. Systematic exploration of the 
delivery system design, as conceptualized by the CCM, is a novel strategy to better 
understanding the factors affecting quality outcomes for persons with a SMI. 
 
 
Practice Standards 
 
The mental health system has various models to guide the delivery of care, which 
focus on treatment with an emphasis on recovery from a mental illness, rather than 
treatment of both physical and mental health concerns. Recovery models in mental health 
systems have transformed the expected outcomes for persons with a SMI. They have 
become the gold standard, enabling greater independence among this population (Frese et 
al., 2001).  Prior to the 1970’s, when deinstitutionalization occurred, persons with a SMI 
were often institutionalized for indefinite periods of time (Lamb & Bachrach, 2001). In 
the 1950’s the discovery of Thorazine showed promise that persons who had been in 
institutions and hospitals could be treated for their mental illness in the community. Over 
the last 60 years the mental health system has shifted the focus of care from housing 
persons with a severe and persistent mental illness to treatment and recovery of persons 
with a SMI. Recovery models are similar to the CCM in that they aim to create the 
structures that instill hope, healing, empowerment, and connection (Jacobson & 
Greenley, 2001). An assumption of the CCM is that the health care system is a barrier to 
the treatment of chronic conditions and as with recovery models, shifting the focus of 
care can lead to quality outcomes based on system redesign (McEvoy & Barnes, 2007).  
 
The delivery of care for persons with a SMI in a CMHC involves a 
multidisciplinary team approach to treatment. Individuals are often treated with 
medication by psychiatrists or Advanced Practice Registered Nurses (APRN’s), who 
have specialty training in psychiatric mental health nursing. Other care team members 
include Master’s or Bachelor’s prepared therapists and case managers, crisis workers, and 
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nursing staff. Team goals include treatment of the person’s psychiatric illness and 
navigation of support for other medical and psychosocial needs. The visit frequency and 
intensity of treatment in the CMHC may vary based on the individual’s severity of illness 
and current needs; however, it is well documented that persons with a SMI need ongoing 
psychopharmacologic treatment of their psychiatric illness. Similarly, in a primary care 
delivery system, persons with chronic physical illnesses receive ongoing 
pharmacotherapy to treat various conditions. SMI treatment involves all phases of the 
illness, including acute illness, maintenance, and relapse.  
 
Historically, persons with a SMI were treated on first generation antipsychotic 
medication. When patients were treated on older, first generation medications, providers 
were concerned about premature death due to unknown factors related to the illness or 
suicide (Brown, 1997; Simpson & Tsuang, 1996).  The use of Atypical Antipsychotic 
(AA) medications as first line treatments have improved psychiatric illness outcomes but 
have also increased cardiovascular health concerns for these patients. Two studies have 
demonstrated that AAs cause weight gain and elevated glucose and lipid levels, and put 
individuals at risk for metabolic syndrome (Hasnain et al., 2009; Patel et al., 2009). The 
cardiometabolic side effect profile of AA medications has further increased the morbidity 
and mortality for this population (Amiel et al., 2008).    
 
The side effects related to AA medications have created heightened awareness of 
the physical health status of persons with a SMI. Studies over the last twenty years have 
shown that AAs have improved treatment of a SMI; however, these medications have 
also been associated with weight gain, hyperglycemia, and dyslipidemia (Morrato et al., 
2010). A seminal study conducted by the National Institute of Mental Health (NIMH) 
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) was designed to 
investigate the effectiveness of antipsychotic drugs in persons with schizophrenia 
(Lieberman et al., 2005). Since the initial study, many secondary analysis studies have 
been published. In one study, persons with schizophrenia who were male had a 34% 
higher risk of coronary heart disease (CHD) while females had a 50% higher risk 
(McEvoy, Meyer, Goff, Nasrallah, Davis, et al., 2005). Diabetes rates were 16% in males 
and 11% in females compared to 3% in the control population. Data from the CATIE 
study found that persons with schizophrenia are at higher risk for CHD. At baseline, 
therefore, cardiac risk factors should be evaluated and monitored. The rate at which 
persons with a SMI develop symptoms which can lead to cardiometabolic syndrome and 
cardiovascular disease has heightened mental health providers’ awareness of the risk for 
persons with a SMI developing cardiometabolic disease. 
 
In response to the alarming rates of obesity, hyperglycemia, hyperlipidemia, and 
hypercholesterolemia, in 2004 the Food and Drug Administration (FDA) published a 
warning letter for mental health providers addressing the risk factors of treating a person 
with an AA. The American Diabetes Association (ADA) along with the American 
Psychiatric Association (APA) developed an expert consensus statement on metabolic 
screening for persons treated on AA medications (American Diabetes Association, 
American Psychiatric Association, American Association of Clinical Endocrinologists, & 
North American Association for the Study of Obesity, 2004). It was hoped that mental 
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health providers would begin to assess the physical health status of persons treated on AA 
medications. However, recent data suggest that in the eight years since the guideline was 
published only a small percentage of persons treated on these medications have been 
screened for cardiometabolic symptoms per the ADA and APA guidelines. Morrato et al. 
(2010) found that 60-80% of psychiatrists surveyed reported monitoring labs regularly; 
however, the study found a 26% compliance rate for baseline glucose screening and a 
10% rate for lipids. Further, Morrato and colleagues (2010) found no significant increase 
in laboratory testing rates after the 2004 publication and highlighted the need for more 
research to address the gap between screening rates for an at risk population.  
 
The reasons for adhering to the ADA and APA monitoring guidelines in 
community mental health centers are unknown. Several published studies have addressed 
cardiometabolic screening rates (Haupt et al., 2009; Hsu et al., 2008; Morrato, 
Newcomer, Allen, & Valuck, 2008; Morrato et al., 2010); however, there are no 
published studies addressing the impact of the delivery system on cardiometabolic 
symptom screening for persons with a SMI. While it is true that researchers are beginning 
to look at cardiometabolic outcomes in this patient population and ways to provide 
integrative care, the data are scant and few published studies exist. Understanding the 
system-related factors that affect recommended cardiometabolic screening and follow-up 
care is critical for improving outcomes for persons with SMI. If health systems, both 
mental and physical health, have the capability for detection of obesity, hypertension, and 
elevated serum lipid and glucose levels at an earlier point in their trajectory, persons with 
SMI can receive the recommended care to address modifiable risk factors through 
planned, timely, medical and behavioral interventions. Earlier intervention will not only 
result in better health outcomes, it will also reduce health care expenditures for this 
patient population. For the above reasons, it is imperative that more is known about how 
the health care system design affects adherence to best practices in order to reduce the 
disparities in care for persons with SMI. 
 
 
Purpose of the Study 
 
The purpose of this study was to describe the impact of the delivery system design 
at a community mental health center and cardiometabolic screening in persons with 
severe mental illness taking atypical antipsychotic medication. Research questions 
include: 
 
1. What are the baseline patient, provider, and visit characteristics of SMI patients 
prescribed an atypical antipsychotic medication?  
 
2. What percent of SMI patients prescribed an atypical antipsychotic medication 
received cardiometabolic screening at a) baseline, b) follow-up, and c) both 
baseline and follow-up?  
 
3. What delivery system characteristics are associated with receiving 
cardiometabolic screening at a) baseline; b) follow-up; and c) both baseline and 
follow-up? 
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Theoretical Framework 
 
 
Quality 
 
This study is guided by the use of the Care Model, an adapted version of the 
Chronic Care Model, and assumes that quality care is patient centered, timely and 
efficient, evidence based, and safe and coordinated. Consistent with the IOM’s (2001) 
definition, quality is defined as the degree in which a mental health service encounter, for 
persons with a severe mental illness, is likely to lead to an outcome of evidenced based 
care as defined by the ADA and APA monitoring guidelines.  
 
The quality of care provided to persons with a severe mental illness can be 
evaluated using the Donabedian model of structure, process, and outcome. As noted by 
Donabedian (1988), the elements of the structure, processes, and outcomes of care need 
to be cited in order for the elements of quality to be identified and clearly stated. The first 
quality care dimension from the Donabedian framework–structure–is defined as the 
CMHC The site where care is delivered is a specialty outpatient clinic which contains 
elements to provide care to persons with a SMI. The processes of care, the second 
element of the Donabedian framework, will identify which components of the delivery 
system design have an impact on care that is patient centered, timely and efficient, 
evidence based, and safe and coordinated. The process quality will evaluate the 
relationship between the patient, provider, and visits to evaluate whether or not the 
practice standard ADA and APA monitoring guidelines were followed. The outcome 
measure will determine the quality of care defined as whether persons with a SMI are 
screened for cardiometabolic symptoms, per the ADA and APA 2004 guidelines at 
baseline and 12 weeks. 
 
 
Chronic Care 
 
Persons with a severe mental illness are in need of ongoing treatment for their 
illness. Chronic care provided to this patient population often occurs in a community 
mental health center where services focus on the mental illness rather than the physical 
health of the individual. Chronic care for persons with a SMI, provided in community 
mental health centers, includes medication management by a health care provider, either 
psychiatrist or nurse practitioner. The chronic care delivered to persons with a severe 
mental illness includes the delivery system design of the mental health center which 
involves a relationship between the patient, provider, and visits. The Care Model 
provides a framework to evaluate the chronic care provided to persons with a severe 
mental illness, specifically evaluating the delivery system design. Within the Care Model, 
the delivery system design incorporates the patient, provider, and visits and allows for the 
evaluation of chronic care quality. 
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Delivery System Design 
 
The Care Model was selected for this study because it includes the IOM 
underpinnings of quality care, which include care that is patient-centered, timely and 
efficient, evidence based, and safe and coordinated. The elements within the delivery 
system design are present in a CMHC. The delivery system design elements include the 
care team consisting of the patient and provider. The other element of the delivery system 
design are visits. These elements are not unique to a CMHC setting and collectively 
influence the quality provided to patients with a severe mental illness. 
 
Chronic care that is patient-centered, timely and efficient, evidence based, and 
safe and coordinated, provided to persons with a severe mental illness in a community 
mental health center can be evaluated for outcomes of evidence based quality care. When 
quality care provided within the delivery system design includes the patient, provider, 
and visit, productive interactions are an outcome. An informed, empowered patient and 
family have productive interactions with prepared, proactive practice teams. 
 
 
Care Outcomes 
 
Within the community mental health center, the structure of the delivery system 
design land the process of how the patient, provider and visits are structured leads to the 
outcome of quality care for persons with a severe mental illness. The care outcome is 
patient screening per the ADA and APA guidelines and referral to primary care if a 
positive screening includes elevated blood pressure, serum glucose, or lipids. Figure 1.1 
displays the Care Model, the adapted version of the CCM, which was used to guide this 
study and describes how the elements of the delivery system design influence 
cardiometabolic screening. 
 
 
Significance of the Study 
 
Persons with a SMI have not only increased morbidity and mortality due to 
unknown risk factors, but also several modifiable risk factors, which if addressed, could 
decrease the number of life years lost prematurely. A growing body of research has 
identified that psychopharmacologic treatment for a SMI has increased the risk of 
cardiometabolic symptoms in this population, placing individuals at higher risk for 
premature death. While research has identified problems related to the side effects of AA 
medications, no studies exist that have examined the delivery system design of a 
community mental health center and the impact on cardiometabolic screening.  
 
The delivery system design of a community mental health center has the same 
components as identified by Wagner and colleges in the Chronic Care Model (1996). 
Within the delivery system design of a CMHC, the care team and visits can be examined 
to explore the effect on cardiometabolic screening in persons with a SMI. To date, one 
study has used the Chronic Care Model to examine organization of the delivery of  
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Figure 1.1. The Care Model 
 
Reprinted with permission. The MacColl Center (2012). The Improving Chronic Illness 
Care Model Elements. In ICIC’s Expanded Chronic Care Model. Retrieved on March 2, 
2010 from: http://www.improvingchroniccare.org/index.php?p=ICIC_Expanded&s=156. 
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behavior health services (Blakely & Dziadosz, 2008). These authors found that 
implementation of the CCM in a mental health agency can help guide change in the 
delivery of behavioral health care. Bauer et al. (2006) and Kilbourne et al. (2009) have 
successfully used adapted versions of the chronic care model to guide care changes with 
persons treated for bipolar disorder. 
 
This study will use the Care Model, an adapted version of the CCM, to guide the 
examination of the delivery system design of a community mental health center to 
identify characteristics of persons with a SMI who are screened and referred for 
cardiometabolic symptoms. The study findings will inform the current body of  
literature about screening for cardiometabolic symptoms and add a novel aspect of using 
the CM elements to guide future work with a focus on the delivery system design. To 
date no published studies have specifically examined the characteristics of the delivery 
system design of a CMHC to explore screening and referral for cardiometabolic 
symptoms in persons with a SMI. The conceptual framework used to guide this study is 
shown in Figure 1.2.  
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Figure 1.2. Delivery System Design Quality  
Conceptual framework: concepts, conceptual linkages and levels of conceptual 
abstraction. 
 
Sources: The MacColl Center (2012); Wagner, E. H., Austin, B. T., Davis, C., 
Hindmarsh, M., Schaefer, J., & Bonomi, A. (2001); Wagner, E. H., Glasgow, R. E., 
Davis, C., Bonomi, A. E., Provost, L., McCulloch, D., . . . Sixta, C. (2001); Wagner, E. 
H. (1998); Wagner, E. H., Austin, B. T., & Von Korff, M. (1996).  
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CHAPTER 2.    REVIEW OF THE LITERATURE 
 
 
The first section of this chapter focuses on the conceptual framework that was 
used to guide this study. The second section of this chapter provides a review of the 
literature centered on the characteristics of the conceptual framework used in this study, 
specifically the delivery system design. Finally, each of the characteristics within the 
delivery system design; the care team, visits, and quality outcomes are discussed. 
 
 
Chronic Care Model 
 
In 1996 Wagener and colleagues introduced the Chronic Care Model (CCM) to 
guide transformation of health care from a system focused on acute illness, to a system 
focused on prevention and chronic disease management. The Chronic Care Model was 
developed in collaboration with the MacColl Institute for Healthcare Innovation after 
extensive literature review on best practices for chronic illness (Figure 2.1). The CCM is 
intended to guide improvement of patient outcomes through six interrelated systems: 
organization of healthcare, community resources, self-management support, delivery 
system design, decision supports, and clinical information systems (Coleman, Austin, 
Brach, & Wagner, 2009). 
 
The CCM conceptualizes health care systems being part of the community in 
which care is provided (Wagner, Austin et al., 2001). The CCM elements were developed 
using the research literature and by health care experts who provide chronic care to 
individuals with various chronic conditions (Improving Chronic Illness Care, 2012). The 
community resources and policies are part of the development of community 
partnerships. Self-management support focus empowers patients to play a central role in 
the management of their chronic illness. Decision support is the use of evidence based 
practice guidelines in daily practice. A clinical information system is the development of 
information systems that prompt patients and providers and performance of the care 
team. Finally, the delivery system design defines the roles of team members to provide 
planned, evidence-based care. Collectively the six elements create a productive 
interaction between an informed activated patient and a proactive practice team to 
improve both functional and clinical outcomes. 
 
 The CCM defines the six broad areas that must be considered but is not 
prescriptive (Glasgow, Orleans, & Wagner, 2001; Hung et al., 2007), an abstract theory 
(Bodenheimer, Lorig, Holman, & Grumbach, 2002) or explanatory theory (Wagner, 
Glasgow et al., 2001). Rather it is a multidimensional solution (Bodenheimer et al., 2002) 
that will guide practice through the interaction of the six systems to develop informed 
activated patients and a prepared proactive practice team. This framework is intended to 
be tailored to various chronic conditions and applied to a variety of care settings and 
populations (Glasgow et al., 2001). The interaction between the six elements of the CCM 
has the ability to improve the quality of preventive and chronic care delivered to patients 
and populations.  
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Figure 2.1. The Chronic Care Model 
 
Reprinted with permission. Wagner, E. H. (1998). Chronic disease management: What 
will it take to improve care for chronic illness? Effective Clinical Practice, 1(1), 2-4.  
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As a highlight of the CCM, Wagner, Austin, and Von Korff (1996) acknowledged 
that the delivery system design is vital in providing quality care to patients. Sperl, Hillen 
et al. (2004) acknowledged interactions of the CCM but also noted that a theoretical case 
can be made to examine individual components of the CCM. For example, health care 
systems are complex and it may be difficult to organize changes needed that comprise all 
six systems in the CCM. Further, organizations have implemented components of the 
CCM and showed an improvement in care (Schmittdiel, Uratsu, Fireman, & Selby, 2009; 
Sperl Hillen et al., 2004). A study conducted by Nutting and colleagues (2007) provided 
data to support the claim that systems do not implement all aspects of the CCM. In this 
study, the findings suggest that implementation of elements of the CCM leads to 
improvement in care of persons with diabetes. Polonsky et al. (2003) also found that 
focusing on self-management support, as an element of the CCM, improved care of 
person with diabetes. Finally, a study of effective diabetes care showed that one aspect 
within the delivery system design, care management, can improve outcomes for persons 
with diabetes (Schmittdiel et al., 2009).  
 
Wagner, Glasgow and colleagues (2001) intended for the CCM to be used in 
various disease states and populations in a variety of settings and to guide transformation 
of care to persons with a chronic condition. The model supports care that is evidence 
based, population based, and patient centered (Glasgow et al., 2001) as well. This model 
is consistent with the Institute of Medicine’s (2001) aims of health care systems to 
provide care that is safe, effective, patient centered, timely, efficient and equitable. To 
address the unique needs of various patient populations in a variety of settings, the CCM 
may need to be adapted to assess quality outcomes. The adaptation of the CCM is 
encouraged by Wagner, Glasgow and colleagues and versions of an expanded CCM that 
include components such as health determinants have been developed (Barr et al., 2003).  
 
The Institute for Health Care Improvement (ICIC) adapted the CCM to include 
four of the six IOM aims of care called the Care Model (CM). After reviewing the 
literature and adapted versions of the CCM, this study used the CM (Figure 1.1) to guide 
the development of the conceptual framework for this study (Figure 2.2). Given the 
national initiatives on patient safety, quality and measurement of health outcomes at the 
individual and system level, the incorporation of the IOM’s underpinnings is critical.  
 
The CM includes the same six elements as the CCM, but it proposes productive 
interactions of an informed empowered patient and family, not an informed activated 
patient and prepared proactive practice teams. The CM also proposes the interplay of the 
key six elements of the model along with the quality initiatives of patient centered, timely 
and efficient, evidence based, and safe and coordinated care. The CM proposes to not 
simply produce functional and clinical outcomes like the CCM, but rather produce 
improved functional and clinical outcomes.  
 
Traditionally, the belief was that with an increase in knowledge patients would 
better adhere to treatment (Wagner et al., 1996), which in turn would translate to 
improved health outcomes. However, with activation or knowledge, change does not 
occur. The ability to foster self-efficacy, empowerment, and health literacy to aid patients  
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Figure 2.2  Study Variables within the Study Conceptual Framework 
 
Sources: The MacColl Center (2012); Wagner, E. H., Austin, B. T., Davis, C., 
Hindmarsh, M., Schaefer, J., & Bonomi, A. (2001); Wagner, E. H., Glasgow, R. E., 
Davis, C., Bonomi, A. E., Provost, L., McCulloch, D., . . . Sixta, C. (2001); Wagner, E. 
H. (1998); Wagner, E. H., Austin, B. T., & Von Korff, M. (1996).  
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health literacy to aid patients in management of illness is central to bringing about change 
and evaluating adherence rates. Another important factor to consider is that patients do 
not impact outcomes without other persons in their life. The CM includes the family, 
which broadly defined can include any important person in the patient’s life. Support 
from important family members, friends, or significant others will impact quality 
outcomes.  
 
Collectively, with the inclusion of the IOM quality aims and focus on productive 
interactions of an informed, empowered patient and family, the CM is more consistent 
with achievement of improved functional outcomes. While no new elements were added 
to the already adapted CCM, called the CM, the synthesis of the concepts, as described 
above, are unique to this author.  
 
The CCM developed in 1998 has been used with funding and support from the 
Robert Wood Johnson Foundation’s (RWJF) Improving Chronic Illness Care (ICIC) 
program (Hung et al., 2007). Inherent receiving funding support from the RWJF in the 
development of a new model to guide proving preventive and chronic illness care, there 
are several strengths and weakness. Additionally, given the young nature of this model 
there are identified gaps in the database and clinical literature along with weaknesses of 
this model.  
 
The ability to receive support and funding from a nationally recognized agency 
such as the RWJF is a strength that the CCM can build upon. The financial and resource 
support obtained by working with a large agency strengthens the ability to develop, test, 
and modify quality initiatives, such as the CCM. Development of the CCM at a time that 
is consistent with the IOM’s (2001) goals to transform health care from a reactive to a 
proactive system of care with a focus on chronic conditions is timely. Both the IOM and 
the CCM have a similar goal to narrow the quality chasm of health care delivery systems.   
 
As described by Wagner, the CCM can address the tyranny of the urgent 
(Bodenheimer & Grumbach, 2007). For example, health care systems have not had 
models to address health prevention and chronic illness care that can systematically 
evaluate quality outcomes. Most health care systems react to what patients request and 
providers focus on the urgent problem, which is consistent with the dual task theory 
(Wagner et al., 1996). The dual task theory would suggest that providers are invested in 
patients and not missing an acute problem or being held liable for omission of care. 
Therefore, care is structured to focus on urgent, acute problems. The CCM has the ability 
to provide a framework to challenge old ways of providing care and to systematically 
evaluate outcomes.  
 
In 2001 it was cited that the CCM model was being used by over 300 diverse 
health care systems in quality improvement efforts related to care of asthma, congestive 
health failure, depression, and diabetes, and to the prevention of frailty in the elderly 
(Wagner, Glasgow et al., 2001). Data to support the feasibility and acceptability of the 
CCM to guide improvement efforts are beginning to be published (Wagner, Austin et al., 
2001). Coleman and colleagues (2009) reported after review of the evidence on the CCM 
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that all studies that used elements of the CCM to evaluate quality showed improvement. 
This finding suggests that the CCM provides a framework for incremental evaluation to 
guide interventions or changes. If findings suggested that as a part of an interacting 
system all six elements of the CCM need to be studied or changes need to be made 
collectively, this would limit the utility of the model. Systems are complex and often 
access to all parts of a system is impractical.  
 
The Assessment of Chronic Illness Care (ACIC) survey was developed by 
Wagner and colleagues to assess the organizational and team presence of the CCM 
(Bonomi, Wagner, Glasgow, & Von Korff, 2002). The original survey is a 25 item 
instrument that measures the six CCM elements and was found to be sensitive to 
organizational change and changes in quality measures of chronic care (Parchman, Zeber, 
Romero, & Pugh, 2007). Two studies found that the ACIC scores for elements of the 
CCM are associated with improvements in quality care for persons treated by diabetes 
(Parchman, et al, 2007; Solberg et al., 2006).  
 
The CCM has been used in many studies to evaluate outcomes for people with 
diabetes. The use of CCM has been shown to be significantly associated with quality 
outcomes of lower hemoglobin A1C levels and lipid levels (Nutting et al., 2007; Piatt et 
al., 2006). Studies have also shown that use of the CCM increases the adherence to 
clinical practice recommendations. Siminerio, Piatt, and Zgibor (2005) found use of the 
CCM with rural patients improved adherence to the standard of care for diabetic patients 
with lower hemoglobin A1C levels and lipid levels. Others found diabetes care improved 
through use of the CCM by lowering rates of hemoglobin A1C levels and increasing rates 
of eye examination referral, dietary counseling, and micro albumin assessment (Chin et 
al., 2004). Improvements were also noted in a feasibility study (Bray et al., 2005) for 
measures of lipid panel assessment, aspirin use, and documentation of a foot 
examination. 
 
A strength of the CCM relates to the adaptability of the model. For example, the 
model has been adapted to evaluate outcomes for persons with Bipolar Disorder, called 
the Bipolar-CCM. The CCM has been adapted specifically to evaluate the outcomes for 
persons with Bipolar Disorder in two Veterans Affairs Medical Centers (VAMC), one in 
the Northeast (Bauer et al., 2006) and one in the Midwest (Kilbourne et al., 2009). Both 
studies suggest that the B-CCM may be an effective model in the treatment of persons 
with Bipolar Disorder; however, studies are limited and the generalizablity of the 
findings from a VAMC population to persons treated in a community mental health 
center are questionable. Further evaluation of outcomes by these authors and others will 
help provide a body of evidence to evaluate the effectiveness of this model.  
 
Adaptation of the CCM to treat older adults who have depression and comorbid 
physical health conditions has been cited. Three programs that guide the treatment of 
older adults with depression and comorbid physical health conditions include the 
Improving Mood Promoting Access to Collaborative Treatment (IMPACT) program, the 
Prevention of Suicide in Primary Care Elderly Collaborative Trial (PROSPECT), and the 
Program to Encourage Active and Rewarding Lives for Seniors (PEARLS) (McEvoy & 
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Barnes, 2007). These authors note that the effectiveness of these programs is related to 
the structure, follow-up, and coordination of care.  
 
Van Cleave and Leslie (2008) provide a theoretical case to use elements of the 
CCM to treat attention-deficit/hyperactivity disorder (ADHD), which is identified by 
these authors as a chronic condition commonly diagnosed in childhood. All six elements 
of the CCM are identified as a “pillar’ and examples of how each element is applied to 
ADHD is provided. For example, the delivery system design is applied to chronic ADHD 
care by creating relationships with primary care for referrals and follow-up treatment. 
While this is not an empirically tested approach, the theoretical case, using clinical 
examples to demonstrate the applicability of the CCM to treatment of ADHD is 
discussed.  
 
Limitations or gaps noted in the literature on the CCM relate to the 
generalizability to persons with a SMI treated in a community mental health center. Only 
one published study on the use of the CCM in behavioral health has been published. This 
study found that the CCM can be used to restructure care and help persons with a mental 
illness better manage their illness and improve social functioning (Blakely & Dziadosz, 
2008). These authors state that the CCM should be further explored to assess whether 
application of the model to persons with a mental illness can better manage both their 
physical and mental health.  
 
A weakness of the CCM relates to those organizations that use all or parts of this 
model to evaluate quality related outcomes. Most of the organizations who have 
implemented this model are part of the Breakthrough Series (BTH) and the motivation to 
organize and implement quality improvement initiatives in these systems is high 
(Wagner, Austin et al., 2001). It has been postulated that organizations with upper 
management support to implement quality evaluation projects will be successful 
regardless of the model used.  
 
Coleman and colleagues (2009) acknowledge the effectiveness of the model but 
do provide a discussion of limitations. First, the CCM is a framework that cannot be 
immediately replicated. Second, the practical nature and cost effectiveness of this model 
have not been fully examined and further research is needed. Finally, organizations that 
are not part of the BTH need to evaluate the model in a systematic, rigorous manner. It is 
important to reiterate that this model is slightly a decade old and many studies are 
underway and their findings have not been published.  
 
 
Conceptual Framework 
 
The CCM and adapted CM were used to guide the development of the conceptual 
framework in this study. While the CCM was developed to guide changes in care 
provided in the primary care setting, the elements as described in the CCM are also 
present in the mental health system of care. Specifically, the delivery system design, as 
described in the CCM and adapted CM, contains elements of a care 
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team and visits. Both elements are present in all health care delivery systems. Further, the 
conceptualization of a care team as a patient and provider is not unique to a primary 
system of care.  
 
The other element in the delivery system design is visits. As part of the CCM, 
visits are planned or scheduled; however, in the mental health system of care visits are 
scheduled or due to crisis. The conceptualization of planned visits in a mental health 
system might develop over time as the delivery system design is better understood. It is 
vital to better understand which elements of the delivery system design impact various 
components of care delivered to persons with a SMI and influence patient centered, 
timely and efficient, evidence based, and safe and coordinated care.  
 
 
Delivery System Design  
 
The delivery system design, a characteristic of a health system, includes structures 
and processes of care delivery that support quality patient care. A delivery system design 
of a community mental health center includes the care team, comprised of the patient and 
provider and the visits. The interaction of the care team and visits has an impact on 
patient care quality outcomes. This section of the literature review focuses on the care 
team, visits, and quality outcomes related to the delivery of mental health services in a 
community health center, to persons with a severe mental illness who are treated on 
Atypical Antipsychotic (AA) medication.  
 
 
Care Team   
 
The care team, a component of the delivery system design, is composed of the 
patient and provider. Elements related to the patient are: age, gender, race and ethnicity, 
language best served, marital status, employment and insurance, tobacco use, diagnosis, 
AA medication use, and whether primary care services are provided within the clinic or 
outside the clinic. Elements related to the provider include provider characteristics: 
degree, certification, number of years practicing as a mental health provider, and number 
of years providing care at a community mental health center.  
 
 
Patient 
 
Persons with a severe mental illness have characteristics that affect the delivery of 
quality mental health services within a community mental health center. The 
characteristics that affect quality related to the individual patient include: age, gender, 
race and ethnicity, language best served, marital status, employment and insurance, 
tobacco use, diagnosis, AA use, and if primary care services are provided within the 
clinic or by a provider outside of the clinic.  
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The onset of a severe mental illness tends to happen early in life, often at a time 
when individuals are transitioning from adolescent stages of development to adulthood. 
There are known gender, race and ethnicity differences in the onset and treatment of 
severe mental illness. Often persons treated in urban areas are from diverse areas or are 
immigrants and do not speak English as a first language. It is known that limited English 
proficiency impacts health seeking patterns, access to care, and health outcomes. Marital 
status, employment status, and insurance also impact access to care and health outcomes. 
Additionally, persons with a severe mental illness have high rates of smoking, co-morbid 
physical health conditions, are treated on AA medications and seek primary care less 
frequently. The patient characteristics noted affect quality outcomes and it is important 
that they be understood and explored.  
 
 
Age. In the U.S. 74.3% of the population is over 18 years of age (U.S. Census 
Bureau, 2010) and persons with a SMI are often diagnosed in young adulthood. Onset of 
a SMI, in early adulthood, prevents individuals from developing and experiencing normal 
emotional growth and development. Various psychiatric illnesses have a slight variation 
in onset of the illness, which also impacts the illness trajectory. Several prevalence of 
mental illness studies have been conducted, which provide data about the age of onset of 
a SMI. The diagnosis of a mental illness is guided by the Diagnostic and Statistical 
Manual IV - Text-Revision (DSM IV- TR), which is the latest diagnostic manual.  
 
Three large lifetime prevalence of Diagnostic and Statistical Manual (DSM) 
disorder studies in national samples have been conducted since the 1980’s. The first study 
conducted was the Epidemiological Catchment Area (ECA) survey, which was funded by 
the National Institute of Mental Health (NIMH). This study surveyed a total of 20,291 US 
residents age 18 and older (Bourdon, Rae, Locke, Narrow, & Regier, 1992). This study 
used the DSM -III criteria for identification of prevalence rates of mental disorders. The 
ECA survey found that about 1 in 5 adults had a mental disorder in a six month time 
frame and about 1 and 3 adults had a lifetime prevalence of a mental disorder; however, 
17.6% received care within six months of the survey (Bourdon et al., 1992).  
 
According the ECA survey, lifetime prevalence of Schizophrenia is 1.5%, of 
Major Depression is 5.9%, and Bipolar Disorder, and with mania is 0.8% (Bourdon et al., 
1992). The ECA survey found that mean age of onset of major depression is 23 years for 
males and 25 years for females and for Bipolar Disorder, age 18 for males and age 20 for 
females (Burke, Burke, Regier, & Rae, 1990). Merikangas and colleagues (2007) used 
the NCS-R data and found mean age of onset for any Bipolar Disorder (Bipolar I or II) 
was 20.8.  
 
The National Comorbidity Survey included a sample of 5877 U.S. adults and used 
the DSM III-R to identify persons with a mental disorder. This study found lifetimes rates 
of major depression to be highest in adults age 35-44 years of age: 14.7% of males and 
23.8% of females (Kessler, McGonagle, Swartz, Blazer, & Nelson, 1993).  
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The most recent study, The National Comorbidity Survey Replication (NCS-R) 
was conducted using the last DSM-IV and included 9,282 English speaking persons over 
age 18 years of age (Wang et al., 2005). These authors note the differences in the delivery 
of mental health services and change in the DSM version III and IV, with IV placing 
more emphasis on the impact of the disorder has on psychosocial functioning may 
identify differing rates of mental disorders.  
 
The Epidemiologic Catchment Areas Study from 1980 and the National 
Comorbidity Survey (NCS) in the 1990’s had similar findings about prevalence rates of 
mental disorders. Kessler and colleagues (2005) used the NCS-R data and found the 
mean age of onset of a mood disorder is age 30, and the prevalence of Major Depressive 
Disorder is 16.6%. The prevalence of Bipolar I or II Disorder is 3.9%. Lifetime risk of 
any mental disorder is 46.4% and after age 60, the risk of a mood disorder declines. The 
NCS reported a prevalence rate of psychotic illness of 2.2% and persons from a younger 
age group are found to have higher rates of schizophrenia (Kendler, Gallagher, Abelson, 
& Kessler, 1996). A psychotic disorder, major depressive disorder, and a bipolar disorder 
are all defined as a SMI.   
 
Studies that examine rates of screening for cardiometabolic illness in persons with 
a SMI related to age are less prevalent. One study conducted with Veterans 
Administration patients found that older age was associated with less lipid and glucose 
monitoring (Copeland et al., 2010). 
 
 
Gender. In the U.S. 49.1 % of the total population is female compared to 50.9% 
which are male (U.S. Census Bureau, 2010). It is well documented in the literature that 
health disparities related to gender exist. The ECA survey and NCS-R survey both found 
that woman are diagnosed with depression at higher rates than men (Burke et al., 1990; 
Kessler et al., 2005). The finding that Major Depression has a higher lifetime prevalence 
in females (21.3%) compared to males (12.7%) was also noted in the NCS-R (Kessler et 
al., 1994). These authors found that lifetime prevalence rates of Bipolar Disorder with 
mania were similar for men and women, 1.6% for males and 1.7% for females. Data from 
the NCS I found rates of schizophrenia were not significantly higher in females than 
males (Kendler et al., 1996).  
 
A secondary analysis of the National Comorbidity Survey Replication (NCS-R) 
data found that women are more likely than men to receive mental health treatment for 
two disorders classified as a SMI; Major Depressive Disorder and Bipolar Disorder 
(Wang et al., 2005).  
 
In relation to gender and screening for cardiometabolic symptoms, few studies 
have examined male and female differences. Two large retrospective analyses from 
claims data found that gender did not impact lipid testing but males received less glucose 
testing then females (Haupt et al., 2009; Morrato, Newcomer, Allen, & Valuck, 2008). 
Moeller and colleagues (2011) found women were more likely to have both lipid and 
glucose screening. In a Veterans Administration population, Kilbourne et al. (2007) 
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found that women were less likely to have lipid monitoring and male nonwhite patients 
received less glucose screening.  
 
 
Race and Ethnicity. In the United States 74.4% of the population is white, Non-
Hispanic, followed by Hispanic / Latino at 16.3%, Black at 12.6% and Asian at 4.8% 
(U.S. Census Bureau, 2010). According to the U.S. Census, the fastest growing race was 
Asians, which grew 14.7 million. From the 2000 Census to the 2010 Census, Hispanics 
grew by 43% to 50.5 million.  
 
The NCS-R data found that Blacks and Hispanics have lower prevalence rates for 
depression compared to non-Hispanic whites, which are consistent with the findings from 
the ECA study (Kessler et al., 1994).  Other authors also found, using the NCS-R data, 
that the risk of having a mood disorder was lower for non-Hispanic blacks and Hispanics 
when compared to non-Hispanic whites (Kessler et al., 2005).  
 
A study that examined access to care and adequacy of treatment in depressed 
persons found being non-Hispanic white was associated with accessing and receiving 
adequate mental health care as compared to other ethnic and racial minority groups 
(Alegria et al., 2008). The NCS-R also found that coming from a racial or ethnic minority 
was associated with having unmet mental health needs and receiving less than adequate 
care (Wang et al., 2005). Asians were also found to have the lowest use of mental health 
service utilization when compared to White, Hispanic, and Native American racial and 
ethnic groups but was similar to Blacks (Lee, Martins, Keyes, & Lee, 2011). This study 
had few Asian subjects who were born in the U.S. and high rates of recent immigration.  
 
A large National Survey of 134,875 adults had similar findings that Mexican 
Americans, Hispanic-Latinos, and Asians had lower rates of mental health service 
utilization, as compared to Whites (Harris, Edlund & Larson, 2005). This same study 
found that American Indians and Native Alaskans had disproportionately high rates of 
mental health problems and African Americans had better mental health than Whites.  
 
Medication selection and mental health services utilization have been found to 
have different patterns based on race and ethnicity. A large national data set on outpatient 
claims visits for persons treated on an AA or typical antipsychotic found different 
treatments in ethnic populations (Daumit et al., 2003). This study found that more 
Hispanics and African Americans had a psychotic disorder diagnosis. However, Whites 
received more than half of the AA prescriptions as compared to African Americans, who 
received half the number and Hispanics who received one third the number of AA 
prescriptions. African Americans had a psychotic disorder diagnosis more frequently, as 
compared to Whites.  
 
A smaller study that used secondary data had similar findings. African Americans 
received AA medications at 49% of the visits as compared to Whites who received an 
AA medication 66% of the time (Herbeck et al., 2004). A study of Texas Medicaid 
claims also found that African Americans were less likely to receive a prescription for an 
  
25 
AA compared to whites (Opolka, Rascati, Brown, & Gibson, 2004). These studies used 
data from the late 1990s and early 2000s, at which time fewer AA medications were on 
the market, which might explain some disparities in prescribing.  
 
Copeland et al. (2009) did not find that race or ethnicity were associated with 
different testing rates for cardiometabolic symptoms; however, this study does point out 
that African Americans and Hispanics did receive more follow-up diabetes treatment. 
Hispanic patients are at higher risk for diabetes and were found to have lower screening 
rates, as compared to the national recommendations (Mangurian, Goss, & Newcomer, 
2010).  It is unclear why non-White minority populations access health care at lower rates 
and receive lower care quality (Saha, Chant, McGrath, 2007). 
 
 
Language Best Served. In the United States (U.S.), ethnically diverse populations 
or minority populations, both who are immigrants and those who are U. S. born are on 
the rise. Persons who speak a language other than English in U.S. homes is 18%, but of 
those who do not speak English in the home, over half report speaking English very well 
(U.S. Census Bureau, 2000). Many individuals who do not speak English are from an 
ethnically diverse minority population (Sentell, Shumway, & Snowden, 2007). 
Individuals from minority populations, whose first language is not English, often settle in 
urban areas. Health care centers that are located in urban areas treat ethnically diverse, 
minority populations. English proficiency has been associated with mental health service 
utilization (Bauer, Chen, & Alegra, 2010). 
 
Language barriers are one possible source of limited access to care and lower care 
quality. An inability to understand the language in which health care is provided creates a 
health encounter with a higher likelihood of misunderstanding and lack of follow through 
with treatment recommendations. Having Limited English Proficiency (LEP) and 
presenting for mental health treatment creates a higher likelihood of miscommunication 
and variations in care. A psychiatric diagnosis is made by communicating with an 
individual and this specialty area does not rely on diagnostic tests to make a diagnosis, 
rather on direct communication (Sentell et al., 2007). Patients with LEP are at higher risk 
of health care disparities when seeking mental health services (Kim et al., 2011).  
 
Several studies have shown that LEP is associated with a decrease in perceived 
need for mental health treatment or awareness of having any mental health problems 
among Hispanic and Asian adults (Bauer et al., 2010; Kim et al., 2011; Sentell et al., 
2007). Kim and colleagues found that Latinos live in the U.S. longer, as compared to 
Asians, but have lower LEP. These researchers found that both Asian immigrants had 
lower mental health utilizations rates when compared to U.S. born Asians. In contrast, 
this same study found that Latino immigrants had slightly higher rates of mental health 
utilization as compared to those who are U.S. born. Health service rates were 39.4% of 
Latinos, of which 85% were immigrants. Additionally, just over 34% of the study 
population were Asians, of which 94.9% were immigrants and had LEP.  
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A large study of non-Hispanic and Hispanic adults found that persons who did not 
speak English in the home were less likely to receive recommended general health care 
services (Cheng, Chen, & Cunningham, 2007). This study highlighted that non-Hispanic 
whites who spoke English were more likely to receive eligible care than English speaking 
Hispanics who spoke English at home. Bauer and colleagues (2010) found racial and 
ethnic disparities in treatment of persons with depressive disorders; however, they did not 
find significant differences in quality of care based on LEP. Persons with LEP are found 
to be less insured, have lower education (Bauer et al., 2010; Cheng et al., 2007), be male, 
not married, and have a family income below 200% poverty (Cheng et al., 2007).  
 
 
Marital Status. Persons with a SMI have a chronic mental disorder which has 
episodes of acute exacerbation of illness and periods of stable illness. As with any 
chronic illness, psychosocial support is important in coping with the disease. Because 
persons with a SMI have an illness onset in young adulthood, many do not develop long 
term interpersonal relationships and do not marry.  
 
Data from the NCS-R found the risk of developing a mental disorder or receiving 
treatment is higher for persons who have marital disruption, were previously married, or 
are single (Kendler et al., 1996; Kessler et al., 2005; Wang et al., 2005). Never being 
married is an indicator of delaying mental health treatment and having delays in 
treatment after initial contact (Wang et al., 2005). Marital status can, in some cases be 
used as an indication of social support which can be a protective factor when being 
treated for a mental disorder.  
 
 
Employment, Income, and Insurance. Persons with a SMI have a disorder that 
has periods of stability and episodes of acute illness. The chronic nature of a SMI 
prevents many persons from having sustained gainful employment. Many persons with a 
SMI have a difficult time coping with the stress of holding down a job, have significant 
medication side effects which prevent or limit their ability to function and / or lack 
interpersonal skills to maintain employment. Because of an inability to work, many 
persons with a SMI are on disability or have no income pending a disability application. 
Persons with a SMI who are working and have no income, also do not have insurance. 
Having a chronic mental illness and the nature of the illness prevents many people from 
getting married, which is a source of potential insurance benefits.  
 
The NCS-R studies have shown that persons who are unemployed, are uninsured, 
and have lower income are at risk for developing a mental disorder or receiving treatment 
for a mental disorder (Kendler et al., 1996; Kessler et al., 2005; Wang et al., 2005).  
 
 
Tobacco Use. High rates of smoking have been reported in persons with a SMI. A 
comorbidity study found that 74% of persons with a SMI had a history of smoking at one 
point in their life (Sokal et al., 2004). These authors also note that this patient population 
is also at risk for developing emphysema due to second hand smoke and higher 
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associations with other persons who have SMI. Furthermore, smoking has been found to 
place SMI patients at higher risk for coronary heart disease (Osborn, Nazareth, & King, 
2006).  
 
Rates of smoking for persons with a SMI have been reported as much as two to 
three times that of the general population, and in one study more than 30% smoked more 
than a pack a day, and only 14% were ready for smoking cessation (Dixon et al., 2007). 
These studies suggest the importance of assessing tobacco use and offering smoking 
cessation options for persons with a SMI.  
 
 
Diagnosis. It is known that persons with a SMI prematurely lose 10 – 25 years of 
life as compared to the general population (Miller, Paschall, & Svendsen, 2006; 
Richardson et al., 2005). Cardiovascular disease is the most common cause of excessive 
mortality in this population (Capasso, Lineberry, Bostwick, Decker, & St Sauver, 2008; 
Richardson et al., 2005). Persons with SMI have a high prevalence of comorbid 
cardiometabolic risk factors which place these patients at risk for cardiovascular disease, 
which is in part due to independent risk factors in addition to modifiable risks(Morden, 
Mistler, Weeks, & Bartels, 2009). Studies have shown that persons with a SMI have two 
or more chronic conditions which include hypertension, hyperlipidemia, obesity, or 
diabetes (Jones et al., 2004; Kilbourne et al., 2008).  
 
Persons with a SMI had higher rates of hypertension, heart disease, and asthma as 
compared to the general population, with pulmonary illness being the most prevalent 
(Jones et al., 2004). These findings are consistent with findings reporting that persons are 
diagnosed with diabetes at a younger age, have a higher body mass index, and are 
smokers, as compared to those who do not have a SMI (Vinogradova, Coupland, 
Hippisley Cox, Whyte, & Penny, 2010). Finally, a seminal study, Patient Outcomes 
Research Team (PORT) found that persons with schizophrenia had more complaints 
related to high blood pressure, bowel and breathing problems than the general public 
(Dixon, Postrado, Delahanty, Fischer, & Lehman, 1999).   
 
These studies underscore the importance of assessing the physical health co-
morbidities of persons with a SMI. High rates of cardiometabolic illness in persons with 
SMI along with increase in cardiometabolic risk factors associated with treatment on an 
AA highlight the urgency for screening and preventive care in this patient population.  
 
 
Atypical Antipsychotic Medication. Persons with a SMI are treated on first line 
medications known as AA medications. Several studies have been conducted since the 
advent of AA medication in the early 1980’s that evaluated the cardiometabolic risks and 
side effects from this class of medication.  
 
A seminal study noted that “novel” or “atypical” antipsychotic medications were 
associated with weight gain (Allison & Casey, 2001). This study was one of the first that 
examined antipsychotic induced weight gain and noted that studies are lacking that report 
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rates of “diabetes, heart disease, dyslipidemia, and so on among patients gaining various 
degrees of weight” (Allison & Casey, p. 29). This study also noted the potential for 
stopping medication and relapse due to side effects, namely weight gain.  
 
In 2004 the American Diabetes Association (ADA), American Psychiatric 
Association (APA), American Association of Clinical Endocrinologists (AACE), and 
North American Association for the Study of Obesity (NAASO) report provided 
information about the atypical antipsychotic medication, known as second generation 
antipsychotic (SGA) medication and the risk of metabolic abnormalities. From this paper, 
it is noted that Clozapine and Olanzapine have the highest risk for weight gain, risk of 
diabetes, and worsening lipid profile. Risperidone and Quetiapine have less risk, and 
Aripiprazole and Ziprasidone have no effect.  
 
A national, multisite National Institute of Mental Health (NIMH) study called the 
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) examined 
discontinuation rates of antipsychotic medications over 18 months (Stroup et al., 2003). 
This was the first and largest study of its kind that provided data about persons who have 
schizophrenia and use discontinuation rates on older, typical antipsychotic medication 
and the newer, AA. Persons treated on Olanzapine discontinued the medication at the 
highest rates due to metabolic effects and on average, persons switched a typical 
antipsychotic medication at six months (Lieberman et al., 2005). Additional data were 
collected which allowed for meta-analysis of the data and other secondary data analysis 
about metabolic effects of AAs.  
 
 
Primary Care Provider. The data support that the risk of co-morbid medical 
illness is prevalent in persons with SMI and it is important for mental health providers to 
be aware of metabolic illness (Suppes, McElroy, & Hirschfield, 2007). Several studies 
support the recommendation that integrative services would increase screening rates (De 
Hert et al., 2011; Khatana, Kane, Taveria, Bauer, & Wu, 2011;  Mitchell, Delaffon, 
Vancampfort, Correll & De Hert, 2012; Motsinger, Slack, Weaver, & Reed, 2006). 
Barriers to screening have been postulated to be related to payment (Batscha, 
Schneiderhan, Kataria, Rosen, & Marvin, 2010; Kilbourne et al., 2007). Haupt et al. 
(2009) is consistent with the findings from Shi and colleagues (2009) who found that 
persons who had a primary care visit had higher screening rates as did persons who were 
older or had a preexisting metabolic disorder. 
 
 
Provider 
  
 Characteristics of advanced practice registered nurse (APRN) psychiatric nurses 
are not well documented and little is known about workforce data (Hanrahan et al., 
2003). No current studies have published quality outcomes for person with a SMI who 
received care from a psychiatric APRN.   
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A recent national survey of Psychiatric Mental Health Advanced Practice from 
1,899 respondents provided data about psychiatric APRN provider characteristics and 
basic employment data (Drew & Delaney, 2009). Findings indicate that of the 
respondents, the following are board certified by the American Nurses Credentialing 
Center (ANCC) in the following Psychiatric Mental Health Certifications: 56.9% are 
adult clinical nurse specialists and 12.0% are child and adolescent clinical nurse 
specialist, and 22.0% are adult nurse practitioners and 9.1% are family nurse 
practitioners. Less than 6.6% are dually certified in adult and child and less than 8.0% are 
dually adult certified (family nurse practitioner and adult clinical nurse specialist or nurse 
practitioner). From this study, 87.8% are female and 90.3% are White, followed by 2.1% 
Black/African American. The majority of psychiatric APRN’s are self-employed 
(26.3%), followed by those who work for a public community mental health agency 
(25.6%). The APRN’s who work with adults are reimbursed more often by Medicare 
(57.7%) or Medicaid (45.7%), which is statistically significant. Those APRN’s working 
with adults most frequently treat depressive disorders (36.5%), followed by Bipolar 
Disorder (11.5%) and Schizophrenia and other psychosis (3.6%), all of which are 
classified as a SMI. Data from an ANCC survey in 2003/2006 reported that the years of 
experience psychiatric APRNs have is: 0-5 years, 4.1%; 6-10 years, 4.5%, 11-15 years, 
8.9%, 16-20 years, 14.8%, 21-25 years, 20.6% and 26-30 years 18.2% (Hanrahan, 
Delaney, & Stuart, 2011). 
 
Only one study cited the use of nurse practitioners (NPs) and physician assistants 
(PAs) and quality of care for diabetic patients (Ohman Strickland et al., 2008). The 
findings of this study were that NPs were twice as likely to assess hemoglobin A1C 
levels and more likely meet the lipid treatment guideline, as compared to medical doctors 
or PAs. No studies exist that discuss NP characteristics related to the care of persons with 
a SMI and quality outcomes. In contrast, three survey studies were conducted to assess 
psychiatrists’ awareness of adverse metabolic effects on persons with bipolar illness 
(Ketter & Haupt, 2006; Newcomer, Nasrallah, & Loebel, 2004; Suppes et al., 2007). 
Most published data about treatment of mental illness and practice patterns has been 
conducted with psychiatrists.  
 
The survey conducted by Suppes and colleagues (2007) included 390 respondents 
which found the age of the psychiatrist to be age 40-59, and represented all regions of the 
country with the East being more represented than the Midwest.  In this study 94% of 
psychiatrists were aware of the risk of metabolic syndrome and 76% reported making a 
diagnosis of metabolic syndrome. The respondents were aware that elevated glucose and 
triglycerides, abdominal obesity, low HDL cholesterol and elevated blood pressure make 
up the diagnosis of metabolic syndrome. It was reported that baseline measures of family 
history of diabetes and cardiovascular disease were obtained over 75% of the time, blood 
pressure and body mass index over 60% of the time, and plasma glucose and lipid profile 
were obtained over 50% of the time. Waist circumference was obtained less than 20% of 
the time.  
 
These findings are inconsistent with a meta-analysis of 48 studies that found in 39 
of the studies that blood pressure was monitored at baseline about 50% of the time, 
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cholesterol 41.5%, glucose 44%, and weight 47.9% as compared to lipids and 
glycosylated hemoglobin less that 25% of the time (Mitchell et al., 2012). The gap in 
reporting screening and the actual screening rates needs to be further studied (Morrato et 
al., 2010) given the wide dissemination of the recommended screening guidelines and 
low rates of screening (Haupt et al., 2009).  
 
Ketter and Haupt (2006) conducted a mailed self-administered questionnaire and 
analyzed the first 298 surveys that were returned. This survey asked fewer questions 
about provider characteristics and more about monitoring for metabolic concerns in 
bipolar patients. The study survey reported monitoring the following at baseline; weight 
(2%), fasting plasma glucose (13%), and fasting lipid profile (9%).  In this study, there 
were higher rates of monitoring fasting plasma glucose and lipid profile quarterly or 
annually, at 71%. In this survey, 88% of respondents reported monitoring weight at some 
time, 80% did not monitor waist circumference. This study did not report rates of 
monitoring blood pressure. 
 
The Atypical Antipsychotic Therapy and Metabolic Issues (AtAMI) National 
Survey conducted in 2003 included 300 psychiatrists who treated patients with a 
psychotic disorder (Newcomer et al., 2004). In this study the mean years in practice was 
18, and the majority of respondents were in an outpatient practice followed by a ‘solo’ 
practice and treated 100-300 patients per month. The findings of this study indicated 
psychiatrists had awareness of metabolic issues, but rates of screening were not 
consistent with self-report. For example, rates of screening were as follows: blood 
pressure (17%), weight changes (31%), waist circumference (2%), changes in lipids 
(11%), and changes in blood glucose (21%). 
 
 
Visits 
 
The Chronic Care Model identifies visits as part of the delivery system design. 
Visits in the current health system tend to be urgent or scheduled visits, where the 
provider responds to a health complaint. However, the current system of care that is 
reactive and responds to the patient rather than planned care which identifies  patient 
treatment needs related to chronic disease care (Wagner, Austin et al., 2001).  Visits in 
community mental health centers tend to be crisis, scheduled, or on a walk in basis. 
Currently no studies have examined the use of planned visits for persons with a SMI. 
 
Studies have identified that mental health patients, specifically those with a SMI 
have high rates of ‘no shows’ and drop out of care. Persons with a mental illness have no-
show rates of about 20%, which is about twice the rate in other specialties and up to 50% 
of patient who fail appointments drop out of care (Mitchell & Selmes, 2007). A single 
missed appointment has a high association with dropping out of treatment and in this 
study, first appointment fail rates were 36% and follow-up appointment fail rates were 
40% (Killaspy, Banerjee, King, & Lloyd, 2000). However, studies have shown that 
persons who do not show for an initial appointment and do not follow through with care 
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have higher functional impairments and are in greater need of mental health services 
(Centorrino et al., 2001; Killaspy et al., 2000; Zivin et al., 2009).  
 
Research has demonstrated that being a younger male, unmarried with children 
increases no show rates (Zivin et al., 2009). A large epidemiological survey study also 
found that being young, with low income and lack of insurance for mental health 
treatment increases rates of treatment drop out (Edlund et al., 2002). In contrast, the 
NCS-R survey found that being young, married and with lower education levels was 
associated with dropping out of treatment at higher rates after two visits  (Olfson et al., 
2009). This same study found that after the third visit, being Hispanic with low income, 
from lower socioeconomic status, and without health insurance was associated with 
higher treatment drop out. A smaller study found that psychiatric patients who live alone, 
are more acutely ill, have less education, and who have a major affective disorder drop 
out of treatment at higher rates (Centorrino et al., 2001).  
 
The study by Centorrino and colleagues (2001) found that routinely scheduled 
appointments for psychotherapy had higher rates of adherence compared to non-routinely 
scheduled medication management appointments. This study suggests that persons with a 
severe mental illness have a chronic illness and that visits, consistent with the chronic 
care model, that are planned or scheduled have a positive impact on adherence. 
Delivering care, specifically planning visits in a routine manner, may improve visit 
adherence, which would also have an impact on quality of care.  
 
 
Quality Outcomes 
 
Quality outcomes for persons with a SMI treated on an AA medication can be 
measured against current evidence based practices and guidelines. The characteristics of 
quality outcomes for SMI patients treated on an AA medication can be defined by the 
American Diabetes and American Psychiatric Association monitoring guidelines.  
 
Persons diagnosed with a severe mental illness are treated on medication to help 
achieve remission of symptoms and many persons are treated on antipsychotic 
medication. Antipsychotic medications are the first line biological treatment for 
schizophrenia and have an indication for treatment for bipolar disorder and augmentation 
for major depressive disorder with psychosis or a recurrent major depressive disorder 
cite. Since the 1950’s persons with schizophrenia have been treated on first generation 
antipsychotic medication; however, in 1989 the first second generation antipsychotic, or 
atypical antipsychotic medication was approved (ADA et al., 2004). Since 1989 nine 
other atypical antipsychotic medications have been approved by the United States Food 
and Drug Administration (FDA). It has been noted that the newer, atypical antipsychotic 
medications have benefits over older, typical antipsychotic medication; however, there 
have been reports of weight gain, diabetes, and changes in lipid levels (ADA et al., 2004).  
 
In 2004 the U.S. Food and Drug Administration sent out a letter to “Healthcare 
Practitioner” warning prescribers about atypical antipsychotic drugs and the risk of 
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hyperglycemia and diabetes mellitus. The pharmaceutical companies also changed the 
drug labeling of antipsychotic medication in 2004 (Food and Drug Administration ,2004).   
 
In response to the cardiometabolic concerns and the relationship of the atypical 
antipsychotic medications to major medical illnesses, the American Diabetes Association, 
American Psychiatric Association, American Association of Clinical Endocrinologists 
and North American Association for the Study of Obesity published a monitoring 
protocol for patients on AA medication (ADA et al., 2004). The monitoring protocol 
recommends screening at baseline, four weeks, eight weeks, 12 weeks, quarterly, 
annually, and every five years. The recommended screening at baseline and 12 weeks 
include: 1. personal or family history of cardiovascular disease (baseline assessment 
only); 2. weight (body mass index); 3. waist circumference; 4. blood pressure; 5. fasting 
plasma glucose; and 6. fasting lipid profile.  
 
Despite the FDA prescriber letter, drug label change and publication of the ADA, 
APA, AACE, and NAASO monitoring protocol, screening rates for individuals treated on 
AAs remains low. Three large claims data studies on rates of screening for lipid levels 
and glucose levels all showed that screening rates for persons on an AA are low and rates 
did not increase as much as expected after the warning and published monitoring protocol 
(Busko, 2009; Haupt et al., 2009; Morrato et al., 2010).  
 
The study by Haupt et al. (2009) found that baseline lipid testing and follow-up at 
week 12 pre-guideline were about 8% and 10% as compared to 7% and 9%. 
Pre-guideline baseline glucose testing rates were about 17% as compared to 23% 
post-guideline and at 12 week follow-up pre-guideline rates were 15% and post-guideline 
rates were 18%. A study by Morrato and colleagues (2010) also found low rates of 
baseline testing before the warning; 26% had baseline serum glucose and 10% had 
baseline lipid testing. Post warning did not improve glucose testing rates and a small, but 
statistically significant increase of 1.7% in baseline lipid screening was reported.  
 
The other pre-guideline and post-guideline claims data study by Busko (2009) 
found, at a statistical significance, that there were modest improvements with baseline 
lipid levels of 8.4% and post-guideline levels of 10.5% and baseline glucose levels of 
17.3% and post-guideline rates of 21.8%. Only one study found higher rates of screening 
by psychiatrists and supported that this specialty area is more aware of the need to screen 
and does so at higher rates (Moeller et al., 2011).  
 
Atypical Antipsychotic medication prescribing trends found that post warning, 
prescribing of Olanzapine was prescribed less, but Aripiprazole prescriptions increased 
(Haupt et al., 2009). Several studies noted that switching medication was a strategy to 
deal with cardiometabolic risk factors (Mangurian et al., 2010; Shi et al., 2009).  It is 
noted that persons with a severe mental illness (SMI) have more contact with the mental 
health system of care (De Hert et al., 2011). The ADA and APA guideline (ADA et al., 
2004) does provide monitoring guidelines; however, resistance to evidence based 
practices (EBP) in psychiatry exists.  
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Making a diagnosis in psychiatry is less of an exact science and the Diagnostic 
Statistical Manual (DSM IV -TR) provides criteria; but individuals often have overlap or 
mixed symptoms (Levine & Fink, 2006; Hannes, Pieters, Goedhuys, & Aertgeerts, 2010; 
Williams & Garner, 2002; Maier, 2006). Also, in psychiatry the patient, provider 
relationship has been shown to help individuals improve (Williams & Garner; Hannes et 
al., 2006). One study found that psychiatrists were skeptical of the ability of research to 
be applied into practice because many randomized control trials exclude patient profiles 
that are seen in the community (Hannes et al., 2010). Others note that in psychiatry EBP 
is difficult to apply when this patient population needs holistic, culturally-specific care 
that develops out of the relationship (Williams & Garner, 2002).  
 
 
Summary 
 
 The review of the literature presented in this chapter identifies the current 
research on quality outcomes in persons with a severe mental illness, specifically related 
to cardiometabolic screening for persons treated on an AA medication. While the review 
of literature identifies studies on screening rates, a gap in the literature about the delivery 
system design of a mental health center and its effect on cardiometabolic screening for 
persons with a severe mental illness is identified. The study investigator hopes the 
findings of this study will contribute to the state of science about the delivery system 
design of a community mental health center and identify further research questions that 
can be explored which could have an impact on the quality of care provided to this 
patient population. 
 
  
34 
CHAPTER 3.    METHODOLOGY 
 
 
This chapter includes the research questions for this study, followed by the 
methods used to answer these questions. The research questions for this study were 
developed through a synthesis of the literature and theoretical framework described in 
Chapters 1 and 2. Included in this chapter are the study design, setting, sample, variables, 
procedures, analysis, and methodological assumptions and limitations.  
 
 
Research Questions 
 
 The research questions for this study include:  
 
1. What are the baseline patient, provider, and visit characteristics of SMI patients 
prescribed an atypical antipsychotic medication?  
 
2 What percent of SMI patients prescribed on an atypical antipsychotic 
medication received cardiometabolic screening at a) baseline, b) follow-up, and 
c) both baseline and follow-up?  
 
3. What delivery system characteristics are associated with receiving 
cardiometabolic screening at a) baseline, b) follow-up, and c) both baseline and 
follow-up? 
 
 
Study Design 
 
This study was designed to measure the effect of the delivery system design of a 
community mental health center (CMHC) on the provision of quality care for SMI 
patients who are at high risk for developing cardiometabolic illnesses. A cross-sectional 
design using baseline and 12 week (± 4 weeks) patient health information (PHI) data was 
used. The initial treatment phase is defined as the first 16 weeks of treatment.  
 
This descriptive cross-sectional study used existing SMI patient health 
information for the retrospective analysis of screening rates based on the American 
Diabetic Association (ADA), American Psychiatric Association (APA), American 
Association of Clinical Endocrinologists (AACE), and North American Association for 
the Study of Obesity (NAASO) monitoring protocol for persons treated on a second 
generation antipsychotic (SGA) medication. The monitoring guideline will be referred to 
as the ADA and APA screening guideline. Evaluation of baseline, 12 week, and both 
baseline and 12 week adherence to the ADA and APA guideline will be evaluated. In 
addition, rates of screening for each individual measure within the ADA and APA 
guideline were evaluated. Per the ADA and APA guidelines, persons should be screened 
at 12 weeks; however, due to appointment adherence rates and scheduling of mental 
health patients in a CMHC, the 12 week screening will be evaluated at 12 weeks ± 4 
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weeks. The initial treatment phase is defined as the first 16 weeks. Thus, the first 16 
weeks defines the initial treatment phase.   
 
This study design used retrospective data collection of existing data from an 
electronic health record (EHR). Retrospective electronic health record studies lack an 
approach to methodological consistency. Data in the electronic health record were not 
entered for research purposes but rather for documentation of patient encounters. 
Extracted retrospective data have not been systematically reviewed and therefore do not 
allow for replication, without significant data collection efforts (Dean et al., 2009; 
Gearing, Mian, Barber, & Ickowicz, 2006; Panacek, 2007). In psychiatry, retrospective 
research has been underutilized possibly due to unclear benefits and methodology 
limitations (Gearing et al., 2006). 
 
While there are identified limitations to retrospective data collection, the 
systematic use of electronic health record data allows for analysis of clinical encounters 
to assess quality outcomes. Electronic health record data are often used in clinical 
research, and published studies outline best practices when using raw clinical data (Engel, 
Henderson, Fergenbaum & Colantonio, 2009). However, a strength of retrospective data 
collection, using clinical information extracted from an electronic health record, is the 
ability to access large volumes of information on a cohort or subgroup within the cohort 
(Dean et al., 2009; Roos, Roos, Fisher, & Bubolz, 1990). Retrospective studies using 
electronic medical records are inexpensive and allow for access to real word data (Dean 
et al., 2009). 
 
Guidelines developed by several authors (Gearing et al., 2006; Panacek, 2007) 
were used to address data validity in this study. Clear guidelines on how data were 
extracted  were developed prior to data collection and followed throughout the study. All 
missing data was coded the same. The inclusion and exclusion criteria were followed and 
the identified variables were collected in a systematic manner. The clearly defined 
variables were manually extracted from the electronic medical record by the study 
investigator or electronically extracted by the data extractor.  Missing data were treated as 
random events, occurring by chance rather than deliberate omission. All study variables 
were analyzed, and those without variability were excluded. Thus, candidate attribute 
variables were identified and used in the analysis.  
 
 
Study Setting 
 
The data for this study were obtained from a Community Clinic located in the 
Midwest region of the United States (U.S.). The clinic was founded in 1966 with a 
mission to provide primary care services to children and low income families. The clinic 
is owned and governed by a public university and since inception the mission has 
expanded to advance the well-being of people experiencing health disparities. The 
clinical services include medical, dental, mental health, social work, pro bono legal work, 
and a reading program for children. The clinic is located in an urban neighborhood that is 
home for immigrant populations from Southeast Asia, East Africa, and Central America.  
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During the study inclusion period of 01/01/2010 - 12/31/2010, the clinic provided 
behavioral, dental, and medical care to 11,821 unique individuals. There were 3,714 
unique persons served during this period, who received at least one behavioral, dental, 
and medical service. During this time, 1,886 unique persons received only behavioral 
health care and of that number, 977 encounters were a new patient visit, unique to 
behavioral health.  In 2010, 93% of patients were considered indigent with 92% having a 
form of public insurance.  
 
 
Study Sample 
 
The study inclusion criteria are: a) newly admitted to behavioral health between 
January 1, 2010 and December 31, 2010; b) had a new intake and one follow-up visit 
within the first 12 weeks of treatment; c) age 18 or older; d) had a primary Axis I 
Diagnostic and Statistical Manual IV Text Revision (DSM IV TR) Disorder including 
one of the following: Major Depressive Disorder, Bipolar I or II Disorder, Schizophrenia, 
Schizoaffective Disorder or Psychotic Disorder NOS; and e) treated on an AA 
medication. Study exclusion criteria are: a) an existing clinic patient; b) started on an AA 
medication after the first visit; c) had primary Axis I DSM IV TR disorder of Major 
Depressive Disorder, Bipolar I or II, Schizophrenia, Schizoaffective Disorder or 
Psychotic Disorder NOS made after the first visit; and d) under 18 years of age. The 
study period was from 01/01/2010 - 04/22/2011. Time inclusion was determined by 
having a CPT billing code of 90801 (new intake) and at least one 90862 (follow-up) visit 
for medication management within 12 weeks of the 90801. Having a co-morbid Axis I or 
II psychiatric condition or an Axis III medical condition did not exclude an individual.   
 
 
Instruments 
 
Care delivery system design variables for this study were selected from the 
electronic health record guided by Care Model and the American Diabetes Association 
and American Psychiatric Association monitoring guidelines. Selections of care team, 
visit, and quality outcome variables were guided by a review of the literature in Chapters 
1 and 2. The care team defined as the patient includes 16 variables and the provider 
includes five variables. The visits include six variables. There are five baseline and four 
12 week quality outcome variables.  
 
Study variables and quality outcome variables in relation to the theoretical 
framework are provided in Figure 2.1. A description of study variables for the care team, 
including the patient and provider, visits, and quality outcomes follows and includes 
operational definitions, new variables, and location of variables in the electronic health 
record.  
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Care Team Variables 
 
 
Patient 
 
The care team variables are elements of the delivery system design. The first 
component of the care team is the patient. Specifically, the patient variables studied 
include: age, gender, race, ethnicity, language best served, marital status, employment 
status, type of insurance, federal poverty level, smoking status, clinic primary care 
provider, AA medication, and DSM IV-TR axis I-III and V diagnosis. Table 3.1 provides 
a description of the patient variables, measures, scoring guidelines, and location in the 
electronic medical record.   
 
 
Age 
 
Age, specifically age in years, is associated with the onset of a severe mental 
illness. The mean age of onset of a mood disorder is 30 (Kessler et al., 2005) and younger 
adults have higher rates of schizophrenia (Kendler, Gallagher, Abelson & Kessler, 1996). 
After the age of 60, the risk of having a mood disorder declines (Kessler et al., 2005). At 
admission to the clinic, the patient is asked to self-report date of birth which is calculated 
into age in years. Thus, patient age in years at baseline was analyzed.  
 
 
Gender 
 
Gender differences exist in rates of mood and thought disorders. Women are 
diagnosed with depression at higher rates than men (Berke et al., 1990; Kessler et al., 
2005). Women are also more likely to receive mental health treatment for Major 
Depressive Disorder and Bipolar Disorder (Wang et al., 2005). A national survey study 
found rates of Schizophrenia are not-significantly higher in females than males (Kendler 
et al., 1996). At admission to the clinic, the patient is asked to self-report gender, male or 
female. Thus, patient gender at baseline was analyzed and male gender is identified as the 
candidate attribute.  
 
 
Race and Ethnicity 
 
 Racial and ethnic disparities exist related to seeking mental health treatment and 
rates of treatment of mental disorders. Blacks and Hispanics have lower rates for 
depression compared to non-Hispanic whites (Kessler et al., 1994; Kessler et al., 2005). 
Non-Latino whites have higher access to and receive adequate mental health treatment 
compared to other ethnic and racial minority patients. (Alegria et al., 2008). Additionally, 
coming from a racial or ethnic minority is associated with having unmet mental health 
needs and receiving less than adequate care (Wang et al., 2005). At admission to the 
clinic, the patient is asked to self-report race and ethnicity. Patient race 
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Table 3.1. Care Team: Patient – Measures, Scoring Guidelines and Electronic Health Record for Study Variables 
 
Care Team: Patient Variables  Measure and Scoring Guidelines EHR Module/Field 
Age Measure:  Age at baseline 
Score: Number of years 
Demographics 
Gender Measure:  Self-reported gender at baseline 
Score:  0 = Female  1 = Male  
Demographics 
Race Measure:  Self-reported race at baseline 
Score:  White: 0 = no; 1= yes 
Additional data 
Hispanic Ethnicity Measure:  Self-reported ethnicity at baseline 
Score:  Hispanic: 0 = no; 1 = yes 
Additional data 
Marital Status Measure: Self-reported marital status at baseline 
Score:  Married:0 = no; 1 = yes 
Additional data 
Employment Measure: Self-reported employment status at baseline 
Score:  Working: 0 = no; 1 = yes 
Additional data 
Language Best Served Measure: Self-reported language preference at baseline 
Score:  English: 0 = no, 1 = yes 
Additional data 
Insurance Measure:  Self-reported or proof of insurance status at baseline 
Score:  Public insurance: 0= no; 1 = yes 
Insurance 
Federal Poverty Guideline Measure:  Proof of household income at baseline 
Score:  Below federal poverty guideline: 0 = no; 1 = yes 
Additional data 
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Table 3.1. (Continued) 
 
Care Team: Patient Variables  Measure and Scoring Guidelines EHR Module/Field 
Tobacco Use Measure:  Self-reported and documented by medical assistant 
or LPN at baseline 
Score:  Current smoker: 0 = no; 1 = yes 
Patient chart 
Axis I Diagnosis Measure:  Diagnosis by the medical provider at baseline 
Score:  Mood disorder: 0 = no; 1 = yes 
Patient chart  
Axis III Diagnosis Measure:  Diagnosis by the medical provider at baseline 
Score:  Cardiometabolic Illness (CMI): 0 = no; 1 = yes 
Patient chart  
Primary Care Provider (PCP) Measure:  Clinic primary care provider 
Score:  0 = no; 1 = yes 
Patient chart  
Name of Atypical Antipsychotic 
(AA) at Baseline 
Measure:  Highest risk AA medication 
Score:  Low weight gain: 0 = no; 1 = yes 
Patient chart/Medcin 
Name of Atypical Antipsychotic 
(AA) at Follow-Up 
Measure:  Highest risk AA medication 
Score:  Low weight gain: 0 = no; 1 = yes 
Patient chart/Medcin 
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is self-reported as: African American, Cambodian, European American, Hmong, Laotian, 
Mexican, Ojibwe, Other American Indian Tribes, Somali, Vietnamese, or Other. 
Ethnicity is self-reported as: Hispanic or Non-Hispanic. White race and Non-Hispanic are 
identified as the candidate attributes. Thus, patient race and ethnicity at baseline were 
analyzed.  
 
 
Language Best Served 
 
 Language barriers are one possible source of limited access and lower mental 
health care quality. Several studies have shown that limited English proficiency is 
associated with decreased perceived need for mental health treatment or awareness of 
having any mental health problems among Hispanic and Asians adults (Bauer et al., 
2010; Kim et al., 2011; Sentell et al., 2007). At admission to the clinic, the patient is 
asked to self-report preferred language. Self-reported language best served was reported 
as Somali, English, Spanish, Vietnamese, Ormo, Hmong, Cambodian, or Other. English 
speaking was identified as the candidate attribute. Thus, language best served was 
analyzed.  
 
 
Marital Status 
 
The risk of developing a mental health disorder or receiving treatment is higher 
for persons who have marital disruption, were previously married, or are single (Kendler 
et al., 1996; Kessler et al., 2005; Wang et al., 2005). Never being married is an indicator 
of delaying mental health treatment and having delays in treatment after initial contact 
(Wang et al., 2005). At admission to the clinic, the patient is asked to self-report marital 
status. Marital status was self-reported as: single, married, divorced, separated, life 
partner, legal separation, or unknown. Single/widowed/divorced was identified as the 
candidate attribute. Thus, marital status was analyzed.  
 
 
Employment, Income and Insurance 
 
Persons with a severe mental illness have a chronic mental disorder which 
includes periods of stability and episodes of illness. Persons who are unemployed, 
uninsured, and have a lower income are at risk for developing a mental disorder and 
receiving treatment for the disorder (Kendler et al., 1996; Kessler et al., 2005; Wang et 
al., 2005). On admission to the clinic, the patient is asked to supply information or self-
report employment status, income, and insurance. Employment status was self-reported 
as: full-time, part-time, or none. Unemployment was identified as the candidate attribute. 
Candidate attributes were not selected for income and insurance due to lack of variability. 
Thus, employment status, poverty level, and insurance were analyzed.  
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Tobacco Use 
 
Persons with a severe mental illness smoke at higher rates than the general 
population. Rates of smoking have been reported in persons with a severe mental illness 
as many as two to three times the general population, 30% of which smoke more than one 
pack a day (Dixon et al., 2007). Before seeing a medical provider at each visit, the patient 
is asked by the rooming medical assistant or licensed practical nurse to self-report current 
smoking status. Tobacco use was self-reported to the medical assistant or licensed 
practical nurse as: current smoker, former smoker, or never. Current smoker was 
identified as the candidate attribute. Thus, current smoking status was analyzed.  
 
 
Primary Care Provider 
 
Persons with a severe mental illness have a high risk for co-morbid physical 
health problems. Persons who have a primary care provider have higher physical health 
screening rates (Haupt et al., 2009; Shi et al., 2009). Patients can access primary care 
services at the clinic or see an outside primary care provider. Documentation in the 
electronic health record identifies if a patient had a primary care visit at the clinic within 
the initial treatment period. Having a clinic primary care provider was identified as the 
candidate attribute. Thus, if the patient had a primary care provider visit during the initial 
treatment phase was analyzed.  
 
 
Diagnosis 
 
 The Diagnostic and Statistical Manual IV Text Revision (DSM IV TR) provides 
diagnostic criteria to make a mental disorder diagnosis. The diagnoses are documented on 
a five Axis system. Axis I is the major mental disorder, Axis II is a personality disorder, 
Axis III is the medical disorder, and Axis V is the global assessment of functioning. At 
baseline, the psychiatric provider makes Axis I-V diagnosis and documents the diagnoses 
in the medical record.  
 
For Axis I, Mood Disorders included Major Depressive Disorder, Bipolar I 
Disorder, or Bipolar II Disorder; and Thought Disorders included Schizophrenia, 
Schizoaffective Disorder, or Psychotic Disorder NOS). A secondary Axis I diagnosis was 
confirmed through documentation of a substance use disorder (SUD) by the psychiatric 
provider.  
 
Axis III diagnosis was confirmed through documentation by the psychiatric 
provider of one or more cardiometabolic illnesses (CMI), including hypertension, 
obesity, diabetes, or hyperlipidemia. Persons with a severe mental illness have higher 
comorbid cardiometabolic risk factors (Morden, Mistler, Weeks & Bartels, 2009) and are 
diagnosed with two or more chronic conditions which include hypertension, 
hyperlipidemia, obesity, or diabetes (Jones et al., 2004; Kilbourne et al., 2008). Assessing 
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the physical health co-morbidities and functional level are important when treating 
persons with a severe mental illness.  
 
Axis V is documented as the global assessment of functioning which is a number 
1-100.The global assessment function indicates the overall functional level of a patient, 
which can serve as in indicator of ability to present for appointments and engage in 
treatment. Axis II is a diagnosis of personality disorder, which can also serve as an 
indicator of a patients’ ability to engage in treatment. Candidate attributes for diagnosis 
includes documented Mood Disorder, Axis I SUD, and one or more CMIs. Axis II and V 
do not have an identified candidate attribute. Thus, Axis I primary and secondary SUD, 
and Axis III diagnosis of a CMI were analyzed.  
 
 
Atypical Antipsychotic Medication 
 
 Persons with a severe mental illness are treated on first line medications known as 
atypical antipsychotic medications. Atypical antipsychotic medications have been 
associated with hypertension, obesity, and diabetes, leading to cardiovascular disease 
(Amiel, Mangurian, Ganguli & Newcomer, 2008). Of the atypical antipsychotic 
medications on the market, all are known to increase risk of weight gain, diabetes, and 
worsening lipid profile; however, some place persons at higher risk than others. Highest 
risk AA medications include Quetiapine Fumarate, Olanzapine, Risperidone, or 
Clozapine. High risk AA medications include Aripiprazole, Ziprasidone, or Paliperidone. 
Therefore atypical antipsychotic medication can be placed into two categories; those that 
have the highest risk of cardiometabolic side effects and those that have a high risk. At 
baseline and follow-up, the psychiatric provider prescribed a high risk or highest risk 
atypical antipsychotic medication. Highest risk AA medication was identified as the 
candidate attribute. Thus, AA medication at baseline and follow-up was analyzed.  
 
 
Provider  
 
Within the delivery system design care team, the final variable of interest is the 
provider. Specifically, the provider variables of interest include: highest level of 
education; American Nurses Credentialing Center certification; Second Nurse 
Practitioner certification; Length of time in practice as an Advanced Practice Nurse; and 
Length of time at the clinic. The variables, measures, scoring guidelines and location in 
the electronic health record are found in Table 3.2. 
 
 
Education 
  
 To become an Advanced Practice Psychiatric Mental Health Provider, the 
minimum level of education is a Master of Science in Nursing. Some Advanced Practice 
Psychiatric Providers have additional education such as a Doctor of Nursing Practice,  
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Table 3.2. Care Team: Provider – Measures and Scoring Guidelines for Study 
Variables 
 
Care Team: Provider Variables  Measure and Scoring Guidelines 
  
Highest Level of Education Measure:  Master of Science in Nursing 
Score: 0 = no; 1 = yes 
American Nurses Credentialing Center 
(ANCC) Psychiatric Certification 
Measure:  Nurse Practitioner certification 
Score: 0 = no; 1 = yes 
Second Nurse Practitioner Certification Measure:  Second Nurse Practitioner 
certification 
Score: 0 = no; 1 = yes 
Years in Practice as Advanced Practice 
Nurse 
Measure:  Novice in practice 
Score: 0 = no; 1 = yes 
Years in Practice as Advanced Practice 
Nurse at Clinic 
Measure:  Novice at clinic  
Score: 0 = no; 1 = yes 
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Educational Doctorate or Doctor of Philosophy. The Doctor of Nursing Practice has been 
developed and implemented as the new clinically focused doctoral degree. No current 
workforce data is available about clinical outcomes by Advanced Practice Psychiatric 
Providers who have a Master’s degree, compared to those with a Doctorate Degree. 
However, one can postulate that the additional education and obtaining a clinical 
doctorate would improve patient care outcomes. Having a Master’s in Nursing as the 
highest level of education is identified as the candidate attribute. Thus, highest level of 
education was analyzed.  
 
 
Certification 
 
Advanced Practice Psychiatric Mental Health Providers are prepared as 
Psychiatric Clinical Nurse Specialists or Psychiatric Nurse Practitioners. According to the 
National Organization of Nurse Practitioner (NONPF) competencies, Psychiatric Nurse 
Practitioners are required to complete course work in advanced health assessment and 
have clinical hours in physical health assessment (NONPF, 2003). Some Nurse 
Practitioners have a dual certification in a medical specialty, such as Family Nurse 
Practitioner, Adult Nurse Practitioner, or Acute Care Nurse Practitioner. One can 
postulate that Psychiatric Nurse Practitioners and those psychiatric providers who have a 
secondary medical nurse practitioner certification are more astute to the medical 
presentation of a patient. Having a Psychiatric Nurse Practitioner Certification and a 
Secondary Medical Nurse Practitioner Certification are identified as candidate attributes. 
The type of Psychiatric Certification and having a Secondary Medical Nurse Practitioner 
Certification are identified as the candidate attributes. Thus, Psychiatric Certification and 
Secondary Nurse Practitioner Certification were analyzed.  
 
 
Years in Practice as Advanced Practice Nurse 
 
 New providers who recently became certified have been exposed to current 
practice guidelines, as compared to those in practice for many years. Having five or less 
years of experience as a Psychiatric Advanced Practice Nurse is defined as a novice in 
practice and the candidate attribute. Thus, number of years in practice was analyzed.  
 
 
Years in Practice as Advanced Practice Nurse at Clinic 
 
 Providers who are new to a health system require time to understand flow of 
patient care and may be less aware of both medical and physical care of a psychiatric 
patient. Having five or less years of experience in practice at the clinic is defined as a 
novice at the clinic and the candidate attribute. Thus, number of years in practice at the 
clinic was analyzed.  
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Visits 
 
The delivery system design includes the care team and visits. The visit variables 
of interest are the actual visits the patient encountered during the first 16 weeks of 
treatment. Specifically, the actual visits of interest are: Walk in baseline; Walk in follow-
up; Walk in at baseline and follow-up; No shows; Walk-ins, Hospitalizations; Sum of 
visits; and Sum of number of providers. Table 3.3 provides a description of the 
description of the visit variables, measures, scoring guidelines, and location in the 
electronic health record. 
 
 
Walk-In Visits 
 
Visits in a community mental health center tend to be crisis, scheduled, or on a 
walk-in basis. When a patient walks in for care other than at the scheduled visit time, the 
provider often reacts and responds to the patient rather than following a plan of care. 
Planned care for chronic conditions allows a provider to identify patient needs for the 
chronic condition (Wagner, Austin et al., 2001). Having a walk-in visit at baseline, 
follow-up, and both baseline and follow-up were identified as the candidate attribute 
variable. Thus, walk-in visits at baseline, follow-up, and both baseline and follow-up 
were analyzed.  
 
 
Same Provider at Baseline and Follow-Up 
 
 When a patient has the same psychiatric provider throughout the initial treatment 
phase it allows for the development and implementation of a treatment plan. Same 
provider at baseline and follow-up was identified as the candidate attribute. Thus, same 
provider at baseline and follow-up were analyzed. 
 
 
No Show Rate 
 
 Persons with a severe mental illness have been found to have a high no show and 
drop of care at high rates. No show rates among persons with a severe mental illness are 
about twice that of other specialties and up to 50% of those who fail an appointment drop 
out of care (Mitchell & Selmes, 2007). Having one or more no shows during the initial 
treatment phase was identified as the candidate attribute. Thus, the number of no shows 
during the initial treatment phase was analyzed. 
 
 
Total Number of Visits 
 
 The initial treatment phase is defined as the first 16 weeks of treatment. 
Psychiatric visits are scheduled based on patient acuity; however, during the initial  
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Table 3.3. Visit Measures and Electronic Health Record Fields for Study 
Variables 
 
Visit Variable  Measure and Scoring 
Guidelines 
EHR Module/Field 
Walk In Baseline Measure:  Walk in baseline 
Score:  0 = no; 1 = yes 
Patient chart/Chief 
complaint 
Walk In Follow-Up Measure:  Walk in follow-up 
Score:  0 = no; 1 = yes 
Patient chart/Chief 
complaint 
Walk In Baseline & 
Follow-Up 
Measure:  Walk in baseline & 
follow-up visit 
Score:  0 = no; 1 = yes 
Patient chart/Chief 
complaint  
No Show - One or More  Measure:  One or more no 
shows first 16 weeks  
Score:  0 = no; 1 = yes 
Patient chart/Chief 
complaint  
Same Provider Baseline 
& Follow-Up 
Measure:  Same provider 
baseline & follow-up 
Score:  0 = no; 1 = yes 
Patient chart/Chief 
complaint 
Total Measure:  Sum of all visits-first 
16 weeks  
Score:  0 = no; 1 = yes 
Patient chart/Chief 
complaint 
 47 
treatment phase it is likely that a patient is seen every four to six weeks. Thus, the 
number of visits during the initial treatment phase was analyzed. 
 
 
Quality Outcomes 
 
Quality outcomes include AA screening rates at baseline, follow-up and both 
baseline and follow-up. The AA screening rates were analyzed based on the American 
Diabetes Association (ADA) and American Psychiatric Association (APA) 2004 
recommendations for cardiometabolic screening and monitoring for persons treated on an 
AA medication at baseline and 12 weeks. Complete screening at baseline and follow-up, 
in addition to individual screening measures were analyzed. A positive screening is 
guided by the definition of an elevated blood pressure, elevated plasma glucose or lipid 
profile, as defined by the National Cholesterol Education Program (NCEP) (2002). The 
ADA and APA guidelines and NCEP criteria are provided in Table 3.4.  
 
The ADA and APA monitoring guidelines include six screening measures at 
baseline and five measures at 12 weeks. This study identified the initial treatment phase 
as the first 16 weeks of treatment; therefore, baseline is first visit and follow-up is the last 
visit within 16 weeks. Baseline and follow-up screening measures are considered 
complete if the screening measure was completed within four weeks of the baseline or 
follow-up visit. Because waist circumference is not measured at the community mental 
health center, this measure was excluded from analysis. Therefore, the full provision of 
quality care is defined as having all five baseline measures and all four 12 week 
measures. Baseline screening measures include four biological measures and screening 
for personal or family history of cardiovascular disease. 
 
 Biological measures include: weight or body mass index, waist circumference, 
blood pressure, fasting plasma glucose or hemoglobin A1c, and fasting lipid profile. 
According to the ADA and APA monitoring guideline, body mass index should be 
measured; however, due to a priori knowledge, either weight or body mass index was 
measured. Additionally, per the monitoring guideline, fasting plasma glucose should be 
measured; however, due to the frequency of measuring hemoglobin A1c, either fasting 
plasma glucose or hemoglobin A1c was measured. The one non-biological measure, 
which is to be screened at baseline only, is a personal or family history of cardiovascular 
disease. At 12 weeks, or follow-up the following biological measures are to be screened: 
weight or body mass index, waist circumference, blood pressure, fasting plasma glucose 
or hemoglobin A1c, and fasting lipid profile.  
 
The screening measure of family or personal history of cardiovascular disease 
was included in the baseline measure, and if completed at baseline accounted for a 
follow-up. Therefore, five possible screening measures exist at baseline and follow-up. 
The four biological screening measures (weight or body mass index, blood pressure, 
fasting plasma glucose or hemoglobin A1c, and fasting lipid profile) were recorded using 
the exact documented measurement or a missing variable. An order for fasting plasma 
glucose or hemoglobin A1c, and fasting lipid profile was completed by the psychiatric 
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Table 3.4. Quality Outcome Measures 
 
Measures at Baseline & Follow-
Up  
Measure / Defining Level for Positive 
Screen** 
Scoring Guideline  EHR Module/Field 
Personal/Family History of 
Cardiovascular Disease (CVD)†* 
Personal/family history CVD  0 = no, 1 = yes Patient chart/Narrative 
Body Mass Index (BMI)* BMI - Weight in kg/height in  
m2 /≥ 30kg/m² 
0 = no, 1 = yes Patient chart/Vitals 
Waist Circumference* Waist circumference / Men: >40 inches  
Women: ≥35 inches 
Not measured Not measured 
Blood Pressure* Blood pressure / Systolic pressure of  
≥140 mmHg / Diastolic pressure ≥90 mmHg 
0 = no, 1 = yes Patient 
chart/Narrative/Path labs 
Fasting Plasma Glucose (FPG)* Order or completed FPG / value ≥110 mg/dl 
or A1c order / value > 8% 
0 = no, 1 = no Patient 
chart/Narrative/Path labs 
Fasting Lipid Profile* Order or completed fasting lipid 
profile/cholesterol >200 mg/dl;  
triglycerides >150 mg/dl; LDL >130 mg/dl 
0 = no, 1 = yes Patient 
chart/Narrative/Path labs 
†Baseline Measure Only. 
*ADA and APA (2004) Metabolic Monitoring Schedule.  
** National Cholesterol Program (2002). National Institute of Health. National Heart, Lung and Blood Institute. NIH Publication. 
NCEP ATP III Criteria.  
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medical provider. Assessment and documentation of personal or family history of 
cardiovascular disease was completed by the psychiatric medical provider. Measurement 
of weight, height, and body mass index were completed and documented by a medical 
assistant, licensed practical nurse, or registered nurse.  
 
The quality outcome candidate attribute was defined as the total number of 
screening measures performed by the provider at baseline and follow-up. Thus, number 
of screening measures at baseline, follow-up, and both baseline and follow-up were 
analyzed. 
 
 
Procedure 
 
 
Protection of Human Subjects 
 
Prior to data collection, Institutional Review Board (IRB) approval was obtained 
from the University of Tennessee Health Science Center (UTHSC) (Appendix A).  The 
study met the criteria to be an exempt study and a waiver of Health Insurance Portability 
and Accountability Act authorization was approved. The community mental health center 
is within a community health care center, affiliated with an Academic Health Science 
Center; therefore, additional approval was required. A research proposal and the IRB 
approval letter from UTHSC was submitted to the clinic Chief Clinical Officer for review 
with the clinic research team. Prior to receiving any data the study was approved by both 
UTHSC and the clinic research team.    
 
After IRB approval from UTHSC and the clinic research team, a written data 
request was submitted to the clinic data team whose membership included a data 
manager, who served as the data extractor for the study, the director and assistant director 
of information technology, billing administrator, and a clinician. In addition, meetings 
with the clinic data team and data extractor occurred to discuss study variables and 
method for electronic data extraction, prior to receiving any data. To store the data, a 
member of the Information Technology department within the Academic Health Center 
of the University created a shared user directory on the secure network. The password 
protected shared user directory was only accessible to the study primary investigator (PI) 
and the study data extractor, an employee of the University, in the Office of Technology 
Services and a member of the clinic data team. A folder within this directory named 
“DSD” was created to store the data. Data were stored on the directory “DSD” folder and 
on a password protected encrypted memory stick which was kept in the possession of the 
PI at all times.   
 
 
Data Collection 
 
All patient and visit data used in this study were collected from an electronic 
health record (EHR). Seven of the nine Advanced Practice Registered Nurse Psychiatric 
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Mental Health Providers, completed the consent form (Appendix B) and paper survey 
(Appendix C). Two providers were no longer employed by the clinic. Data on one of the 
two providers was obtained by clinic administration, and the other provider data could 
not be obtained.   
 
Patient and visit data were entered by staff of the community mental health center 
located in the community clinic. Psychiatric services were provided by psychiatrists, 
advanced practice registered nurses with a specialty in psychiatric mental health nursing, 
registered nurses, licensed practical nurses, or medical assistants. Demographic patient 
data was entered by the front desk and administrative staff. The only data entered by 
registered nurses, licensed practical nurses, or medical assistances include: weight, 
height, blood pressure, and tobacco status. The clinic EHR is used by both psychiatric 
and medical providers, without any restrictions on access to data. The EHR does not have 
required fields that must be completed before completing an encounter; therefore, some 
data fields had missing data. All missing data were coded using the number “99.” 
 
The initial study sample was identified by electronic extraction of records queried 
by the data extractor and met the study inclusion criteria: a) had a severe mental illness 
defined as one of the following DSM IV TR codes:  Within the Axis I diagnosis inclusion 
criteria for the study, the following diagnostic codes were included:  295.70, 295.90, 
295.60, 295.30, 295.10, 295.20, 296.2X, 296.0, 296.40, 296.4X, 296.5X, 295.7 or 298.9; 
b) age 18 or greater; c) treated on a AA medication: Abilify (Aripiprazole), Clozaril 
(Cloazpine), Fanapt (Iloperidone), Geodon (Ziprasidone), Invega (Paliperidone), 
Lurasidone (Latuda), Risperdal (Risperidone), Risperdal Consta, Saphris (Asenapine), 
Seroquel (Quetiapine) and Zypreza (Olanzapine);. d) had a visit coded as a 90801 (new) 
and at least one visit coded as 90862 (follow-up) within the first 12 weeks of treatment; 
e) newly admitted to behavioral health services during the study period, January 1, 2010 
to December 31, 2010. After query by data extractor using all inclusion criteria, 385 
patients were identified. After manual review of all 385 patient records, 195 patients were 
excluded for the following reasons: 29 patients did not have a SMI diagnosis, 54 patients 
were not new to the system (established patient), 19 patients did not have a follow-up 
visit, 89 patients were not on an antipsychotic medication, and 4 were younger than 18 
years of age. Figure 3.1 provides a summary of the study sample.  
 
The study variables extracted by the data extractor, using a specific written query 
included the following patient characteristics: Axis I, medication, age, gender, race, 
ethnicity, marital status, employment status, language best served, percent of poverty, 
insurance, and tobacco status. These variables were the original data generated in the 
demographics and patient administration modules within the EHR. The raw data provided 
to the investigator were the data values exactly as they were entered into the EHR and 
these data values were placed into an excel spreadsheet. The excel spreadsheet from the 
data extractor was merged with the excel spreadsheet created by the study PI to manually 
collect study variables.  
 
An excel spreadsheet was created and used to collect data. Four tabs were created 
within the excel spreadsheet to organize the data. The tab named “dxmed” had a locked 
top row with labels for the following patient variables: axis I, axis II, axis III, axis V,  
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Patients Extracted from EMR Database Using Inclusion Criteria = 385 
  
↓ 
  
    
 Patients Excluded after Manual Review = 190  
          
           
29 54 19 89 4 
No SMI 
diagnosis 
Baseline visit 
prior to 1/01/10 
No follow-up visit in 
initial treatment phase 
Not prescribed an  
AA medication 
Age < 18 years 
  
↓ 
  
    
  Sample = 190   
     
 
Figure 3.1. Study Sample 
 
 
primary care provider, medication baseline, medication follow-up, and hospitalization. 
Axis I diagnosis and medication were also electronically extracted from the EHR by the 
data extractor and were used as a quality check with the data extracted manually. The tab 
named “labs” had a locked top row with the following quality outcome and patient 
variables: weight, body mass index, blood pressure, glucose, A1C, cholesterol, LDL, 
HDL, triglycerides, referral, and personal and family history of cardiovascular disease. 
The tab named “visits” had a locked top row with the following visit variables: visit date, 
provider at baseline, provider at follow-up, walk in baseline, walk in follow-up, 
scheduled, no show, walk in, and total number of providers. The final tab labeled “demo” 
included patient variables that were extracted from the EHR by the data extractor, using a 
query code, included age, gender, race, ethnicity, marital status, employment status, 
language best served, percent of poverty, insurance, and tobacco status.  
 
The study variables from the “dxmed” tab were manually extracted by the study 
PI from the clinical console module patient chart located within the EHR. The diagnosis 
variables were extracted and written in the columns on the excel spreadsheet using the 
diagnosis name for axis I, II, III and the number for axis V. The in clinic primary care 
variable was extracted and coded ‘1’ for yes and ‘0’ for no. The AA medication name 
was extracted and coded on the excel spreadsheet using a number that was assigned to 
each medication. The variable hospitalization was coded as “0” for no hospitalization or 
the number of hospitalizations within the initial treatment period.  
 
The study variables from the “labs” tab were manually extracted from the clinical 
console module, patient chart within the vitals tab or laboratory tab. Each quality 
outcome variable was manually extracted and the exact number was placed into the 
assigned column in the excel spreadsheet. Missing values were coded using “99.” The 
referral variable was coded as “1” for yes, and “0” for no, for a positive screening value. 
The variable of documentation of personal or family history of cardiovascular disease 
was coded as “1” for yes, and “0” for no.  
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The study variables from the “visits” tab were manually extracted from the 
clinical console within the chart module. The chief complaint area documents the type of 
visit and this was crossed check by looking at the appointment type and reason for the 
encounter. The appointment type is not a required field; therefore, it is not a reliable 
source of visit data. The provider at baseline and follow-up were coded based on a pre-
assigned number. The number of providers in the initial treatment phase was identified 
and coded as a whole number. The number of scheduled, walk-ins, no shows were 
identified and coded as a whole number. Walk in at baseline and walk in at follow-up 
were coded with “1” for yes, and “0” for no.  
 
A written procedure outlining the method for manual data extraction of 
“demodx,” “labs,” and “visits” was developed and provided to the data extractor. An 
online randomizer was used to identify ten percent of the records that would be checked 
for accuracy. The data extractor checked the records and found an accuracy rate of 
greater than 99 percent. After the data was collected and checked for accuracy, the patient 
record number was deleted. The de-identified data set was imported into Statistical 
Package for the Social Sciences (SPSS) version 20.0 for analysis. 
 
 
Analysis 
 
After the data were cleaned, the de-identified data set was imported into SPSS 
version 20.0 for analysis. Because this is a descriptive study, a formal power analysis was 
not conducted (M. Dietrich, personal communication, March 17, 2011).  
 
To answer research question one: “What are the baseline patient, provider, and 
visit characteristics of SMI patients prescribed an atypical antipsychotic medication?” the 
following statistical methods were used. Data values were tested for normality using the 
Fisher test of normality. Continuous study variables (both candidate and quality outcome) 
not meeting the assumptions of normality were summarized using the median, 25
th
 and 
75
th
 interquartile range, and minimum and maximum. Of the three continuous candidate 
variables, age and Axis V diagnosis did not meet the assumption of normality. Normally 
distributed study variables were summarized using the mean ± standard deviation. All 
nominal and ordinal values were summarized using count and percent (frequency 
distribution).  To further describe delivery system characteristics, cross tabulations were 
used. 
 
To answer research question number two: “What percent of SMI patients treated 
on an atypical antipsychotic medication received cardiometabolic screening at a) 
baseline, b) follow-up, and c) both baseline and follow-up?” the following statistical 
methods were used. The individual quality outcome variables were reported using count 
and percent (frequency distribution) at baseline, follow-up, and both baseline and follow-
up.  
 
To answer the final research question: “What delivery system characteristics are 
associated with receiving cardiometabolic screening at a) baseline, b) follow-up, and c) 
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both baseline and follow-up?” the following statistic methods were used. First, the patient 
characteristics were assessed for variability in responses. Seven of the 16 variables, 
which include ethnicity, language best served, marital status, insurance, percent of 
poverty, Axis II and V, were excluded due to lack of variability. The next step was to 
generate candidate variables for use in the analysis. The categorical candidate patient, 
provider, and visit variables were transformed to the presence or absence of their 
respective attribute, coded as 1 = yes and 0 = no. The only continuous candidate variable 
was age. It was not normally distributed. The square root transformation met that 
assumption and was used in the analyses. Finally, the individual quality outcome 
variables at baseline, follow-up, and both baseline and follow-up were generated.  The 
three new continuous quality outcome variables contained the number of quality 
outcomes measured at baseline, follow-up, and baseline and follow-up. Each outcome 
variable had a possible range from zero to five.  
 
Multiple linear regression was deemed most appropriate for addressing the final 
research question because the candidate variables were either binomial (only 2 possible 
categories for each) or were measured on an interval/ratio scale that met normal 
distribution assumptions. There were at least 10 cases for each candidate variable, and the 
quality outcome variable at baseline, follow-up, and baseline and follow-up were 
continuous. Prior to conducting the multiple linear regression analyses, inter-correlations 
among all of the patient and visit candidate variables were generated using Pearson 
correlation coefficients. Provider candidate variables were generated using the Spearman 
Rho correlation coefficients, as it is the correlation coefficient indicated for variables 
with 30 or fewer cases (Polit, 2010, page 202). Not only of interest themselves, an 
evaluation of collinearity (r > 80) between any two variables may be detected.  None of 
the correlations indicated a problem with collinearity. Finally, unadjusted (bivariate) 
correlations of each candidate variable with each outcome variable and adjusted 
(simultaneous multiple linear regress) associations between the patient and visit 
candidate, and quality outcome variables were generated. Because there were only nine 
providers in the study, a multiple regression was not conducted using those data. In 
addition, because the visit characteristics could only be known at follow-up, unadjusted 
and adjusted associations of those characteristics with the number quality outcomes  was 
generated baseline, baseline walk in at baseline only and both baseline and follow-up 
walk in and same provider follow-up only. Analysis of multivariate residuals did not 
identify prediction problems, which is cited as a potential problem that needs to be 
addressed when using multiple linear regression (Polit, 2010). 
 
Within each multiple regression, multicollinearity of the candidate variables was 
assessed using the Variance Inflation Factor (VIF) and tolerance statistics. Neither VIF 
nor tolerance statistics indicated problems with multicollinearity defined by a VIF of over 
10 or tolerance of < 0.1 (Polit, 2010) for any of the regressions. All candidate variables 
proposed by the model used in this study were used in both the unadjusted (bivariate) and 
adjusted (multivariate) analyses. To use only statistically significant unadjusted findings 
in the adjusted analysis results in an overfitting of the data specific to the study used. 
Similarly, backward or step out multiple regression techniques were not used due to the 
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risk of overfitting data and concerns related to lack of replicability (personal 
communication, Mary Dietrich, March 19, 2012).  
 
 
Methodological Assumptions 
 
There are three major assumptions that exist in this study. The first assumption is 
related to the use of the CM as the conceptual framework to guide this study. The CM has 
not been used in any previous studies that examine a mental health center and the rates of 
screening for cardiometabolic symptoms. It is postulated that the components of the CM, 
as discussed and which have been shown to be successful to redesigning primary care 
environments, are also present in a CMHC.  
 
The second assumption of this study is that the delivery system design as 
described in the CM is present in a CMHC setting. It is assumed that the care team and 
visits, within the delivery system design, will have an effect on the rates of screening and 
referral for cardiometabolic symptoms. The third and final assumption made is that the 
identified CMHC that is used to gather data is similar to other CMHC’s that are cited in 
the literature. The rates of screening for cardiometabolic symptoms, in the identified 
CMHC will be compared to national studies and published rates of screening.  
 
 
Methodological Limitations 
 
The major limitation to this study is apparent in the study design. This study is a 
retrospective, cross-sectional, descriptive study. There are limitations inherent in this type 
of study. For example, the data that will be collected is pre-existing and will be retrieved 
from an electronic medical record. This type of design has threats to internal validity, 
specifically data integrity. Additionally, the data will be collected from one CMHC 
located in the Mid-West Region of the U.S., which will place limitations on the 
generalizability of the findings. Finally, only one component of the CM will be examined 
and may not have the ability to provide information on the agency and the ability to 
identify barriers to screening and referral for cardiometabolic symptoms.  
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CHAPTER 4.    RESULTS 
 
 
The study purpose was to examine the impact of the delivery system design of a 
community mental health center on the provision of quality care provided to persons with 
severe mental illness. Specifically, the aim of the study was to examine characteristics of 
the community mental health care team and visits on adherence to recommended 
monitoring protocol for newly admitted patients treated on Atypical Antipsychotic (AA) 
medication.  The investigator first evaluated the descriptive characteristics of the care 
team which included the patient, provider, and visits. The investigator then examined the 
rates of adherence to the American Diabetic Association (ADA), American Psychiatric 
Association (APA), American Association of Clinical Endocrinologists (AACE), and 
North American Association for the Study of Obesity (NAASO) monitoring protocol for 
persons treated on an AA medication. Rates of screening individual measures within the 
monitoring protocol were also analyzed. Finally, simultaneous multiple linear regression 
was used to examine associations between the patient and visit characteristics with 
quality outcome measures. This chapter will discuss the findings of these analyses.   
 
Results of the following research questions will be discussed:   
 
1. What are the baseline patient, provider, and visit characteristics of SMI patients 
prescribed an atypical antipsychotic medication?  
 
2 What percent of SMI patients prescribed an atypical antipsychotic medication 
received cardiometabolic screening at a) baseline, b) follow-up, and c) both 
baseline and follow-up?  
 
3. What delivery system characteristics are associated with receiving 
cardiometabolic screening at a) baseline, b) follow-up, and c) both baseline and 
follow-up? 
 
 
Care Team Patient Characteristics  
 
Nine hundred seventy seven patients were newly admitted to the clinic between 
January 1, 2010 - December 31, 2010. From the administrative data query, 385 patients 
were identified as meeting the study inclusion criteria. After manual review of the 385 
patient records, 195 patient records were found not to meet the study inclusion criteria. 
Of the 195 excluded patient records, four were under age 18; 19 did not have a follow-up 
visit; 29 did not have a SMI diagnosis; 54 were not new to the clinic; and 89 were not on 
an AA medication. Therefore, the final sample consisted of 190 patients. Figure 3.1 
provides a summary of the study sample.  
 
 The mean patient age was 37.13 years with a SD ± 11.7 and a range of 19 - 70 
years. The majority of patients were men (58.4%, n = 111) and most patients were single 
(90.5%, n = 172). More than one-half of the study (53.7%, n - 102) was minority race,  
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though most patients were not Hispanic (95.3, n = 181). The majority of the patients were 
not currently employed (88.9%, n = 169) and nearly one-half of the patients were below 
the federal poverty guidelines (47.4%, n = 90); most patients were enrolled in the 
Medicare or State Medical Assistance program (90.0%n = 171).  
 
More patients in the study were diagnosed with a mood disorder (72.1%, n = 137) 
compared to a thought disorder (27.9%, n = 53) and were treated on an AA medication at 
highest risk for weight gain, elevated blood glucose, and dyslipidemia (76.8%, n = 146). 
Less than half of the patients were self-reported current smokers (45.8%, n = 87) and a 
smaller percentage were diagnosed with a secondary Axis I diagnosis of a substance use 
disorder (36.8%, n = 70). Nearly half of the patients had a primary care provider at the 
clinic (47.4%, n = 90); however, a small number of patients had a cardiometabolic illness 
(22.2, n = 47), and of those who had hypertension, obesity, diabetes, or hyperlipidemia, 
most were male gender (67.0%).   
 
Table 4.1 provides a summary of care team patient characteristics. For all 
continuous variables, measures of central tendency are reported as mean or median, 
depending on the distribution of data values, and standard deviation.  Nominal and 
categorical variables are reported as the percent and frequency. Age did not meet the 
conditions of normality; therefore, the median, 25
th
-75
th
 interquartile range and minimum 
and maximum are reported.  
 
 
Care Team Provider Characteristics 
 
 Data were obtained for eight of the nine providers The majority of the psychiatric 
mental health advanced practice nurses (PMH APNs) had a Master of Science in Nursing 
(MSN) (75.0%, n =  6) as the highest level of education and more were certified by the 
American Nurses Credentialing Center (ANCC) as an Adult Clinical Nurse Specialist 
(50.0%, n = 4 ). Fewer were ANCC certified as an Adult Psychiatric Mental Health Nurse 
Practitioner (PMHNP) (37.5%, n = 3) and only one (12.5%, n = 1) was certified as a 
Family PMHNP. More providers were in practice for five or more years (62.5%, n = 5); 
however, most were in practice at the clinic for five years or less (75.0%, n = 6).  Table 
4.2 provides a summary of the provider characteristics. 
 
 
Visit Characteristics 
 
Most patients (61.6%) did not receive their baseline or follow-up care during a 
scheduled visit, but rather “walked” into the clinic without prior notice. Patients who 
presented as a walk-in at baseline or follow-up were more likely to be a white, male 
diagnosed with a mood disorder and co-morbid Axis I substance use disorder, and 
received primary care services in the clinic. Patients who had the same provider at 
baseline and follow-up (36.3%) were more often a not white female, diagnosed with a 
thought disorder but without a co-morbid Axis I substance use disorder, and received 
primary care services outside of the clinic. Nearly one-half (45.3%) of the patients failed 
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Table 4.1. Care Team – Baseline Patient Characteristics (N = 190) 
 
Characteristic All Patients* (N = 190) 
Age (Median, IQR25-75, Min, Max)† 35.0, 27.0-45.0, 19, 70 
Gender  
Male 58.4 (111) 
Female 41.6 (79) 
Race  
Not White 53.7 (102) 
African American 26.1 (51) 
Somali 15.3 (29) 
Asian 4.7 (9) 
Native American 4.7 (9) 
Mexican 1.6 (3) 
White 46.3 (88) 
Ethnicity  
Not Hispanic/Latino 95.3 (181) 
Hispanic/Latino 4.7 (9) 
Language Best Served  
English 82.1 (156) 
Non English 17.9 (34) 
Somali 11.1 (21) 
Marital Status  
Single/Widowed/Divorced 90.5 (172) 
Married/Partnered 9.5 (18) 
Employment Status  
None 88.9 (169) 
Part or Full-Time 11.1 (21) 
Insurance Coverage  
Medicaid/Medicare/Medical Assistance 90.0 (171) 
Private  5.3 (10) 
None 4.7 (9) 
Federal Poverty Level  
Not Reported 51.1 (97) 
Below Poverty Guidelines 47.4 (90) 
Over Poverty Guidelines 1.5 (3) 
Current Smoker (self-reported)  
Former/Never/Not Reported 54.2 (103) 
Current 45.8 (87) 
Primary Care Provider at Clinic  
No 52.6 (100) 
Yes 47.4 (90) 
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Table 4.1. (Continued) 
 
Characteristic All Patients* (N = 190) 
Axis I Diagnosis (Primary)  
Mood Disorder 72.1 (137) 
      Major Depressive Disorder 38.9 (74) 
      Bipolar I Disorder  24.2 (46) 
      Bipolar II Disorder  8.9 (17) 
Thought Disorder 27.9 (53) 
      Schizophrenia  11.1 (21) 
      Schizoaffective Disorder 9.5 (18) 
      Psychotic Disorder NOS 7.4 (14) 
Axis I Secondary Substance Use Disorder  36.8 (70) 
Axis III Cardiometabolic Illness 22.2 (47) 
AA Medication   
Highest Risk  76.8 (146) 
      Quetiapine Fumarate (Seroquel) 40.5  (77) 
      Olanzapine (Zyprexa) 17.9 (34) 
      Risperidone (Risperdal) 16.8 (32) 
      Clozapine (Clozaril) 1.6 (3) 
      High Risk   23.2 (44)  
      Aripiprazole (Abilify) 18.9 (36) 
      Ziprasidone (Geodon) 3.2 (6) 
      Paliperidone (Invega) 1.1 (2)  
*Other than age, values in this column are percent (frequency). 
† Median, IQR25-75, Min, Max – data not meeting conditions of normality.  
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Table 4.2. Care Team - Provider Characteristics (N = 8) 
 
Characteristic % (n)* 
Education  
Master Science in Nursing 75.0 (6) 
Doctor of Nursing Practice 25.0 (2) 
American Nurses Credentialing Center Certification  
Psychiatric Mental Health Nurse Practitioner - Family 12.5 (1) 
Psychiatric Mental Health Nurse Practitioner - Adult 37.5 (3) 
Clinical Nurse Specialist - Adult 50.0 (4) 
Years in Practice as an Advanced Practice Nurse   
1-3 years 12.5 (1) 
Greater than 3 years but less than 5 years 25.0 (2) 
Greater than 5 years but less than10 years 37.5 (3) 
Greater than 10 years 25.0 (2) 
   Novice in practice (1 - 5 years) 37.5 (3) 
Years in Practice at Clinic as an Advanced Practice Nurse  
Less than 1 year 25.0 (2) 
1-3 years 12.5 (1) 
Greater than 3 years but less than 5 years 37.5 (3) 
Greater than 10 years 25.0 (2) 
   Novice in practice at clinic (1 - 5 years) 75.0 (6) 
*Percent (frequency). 
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to show up for one or more visits during the initial treatment period.  Of those who had 
one or more no show visits, the patient was most likely to be male, with a mood disorder 
but without a co-morbid substance use disorder and a primary care provider outside of the 
clinic. The median number of visits, during the initial treatment phase was 3.7 ± 1.4 
visits. A summary of visit characteristics is provided in Table 4.3. 
 
 
Provision of Quality Care  
 
The second research study question addressed the provision of quality of care by 
asking: What percent of severe mental illness patients treated on an AA medication 
received cardiometabolic screening at a) baseline, b) follow-up, and c) both baseline and 
follow-up?  Table 4.4. presents the research findings to answer this question.  
 
 Following the full American Diabetic Association (ADA), American Psychiatric 
Association (APA), American Association of Clinical Endocrinologists (AACE), and 
North American Association for the Study of Obesity (NAASO) monitoring protocol for 
persons treated on a second generation antipsychotic (SGA) medication no patient met 
the provision of quality care. Evaluation of the biological measures of the monitoring 
protocol (not assessing family and personal history of cardiovascular disease) at baseline 
5.3% of the patients had full biological screening and 1.6% had full biological screening 
at follow-up. Individual evaluation of the quality outcome screening measures found the 
following mean and standard deviation number of measures at baseline (2.0 ± 1.35), 
follow-up (1.82 ± 1.21), and at both baseline and follow-up (1.21 ± 1.02). At baseline and 
follow-up the same number of patients (n = 2) had five screening measures. Patients were 
more likely to have two screening measures at baseline (25%) and follow-up (33.7%) as 
compared to three measures at baseline (27.9%) and follow-up (24.7%). At both baseline 
and follow-up two screening measures (27.9%) was slightly more common than three 
screening measures (21.0%).  
 
 One patient met the provision of quality care at baseline and follow-up (< 1%). 
The characteristics of this patient included: English speaking female diagnosed with a 
mood disorder and co-morbid substance use disorder, non-smoker, without any 
cardiometabolic illnesses who had a clinic primary care provider. The visit characteristics 
of this patient included: no walk-in visits, no no-show visits, with a total of 4 visits during 
the initial treatment phase. This patient had an increase of her body mass index at 
baseline of 24 kg/m
2 
(normal weight) to 29 kg/m
2 
(overweight) at follow-up. Her 
hemoglobin A1c remained the same at baseline and follow-up, 6 mg/dl but her 
cholesterol, Low-density lipoprotein, and Triglycerides were elevated at baseline and 
follow-up. 
 
 At baseline more patients had a blood pressure measure (n = 119), compared with 
body mass index (n = 65), cholesterol (n = 21), or a lipid profile (n = 16). Of the patients 
that had a body mass index at baseline, 46% were obese with a body mass index of 30 
kg/m
 2 
or greater. The maximum body max index was 45 kg/m
 2
. At follow-up, of the 
patients that had a body mass index, 48% were obese and the maximum body mass index  
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Table 4.3. Visit Characteristics (N = 190) 
 
Characteristic % (n)* 
Walk-in Visit at Baseline  
Yes 39.5 (75) 
Walk-in Visit at Follow-Up  
Yes 35.3 (67) 
Walk-in Visit at Baseline & Follow-Up  
Yes 13.2 (25) 
Same Provider at Baseline & Follow-Up  
Yes 36.3 (69) 
One or More No Show Appointments
†
  
Yes 45.3 (86) 
Total Number of Visits
†
 3.7 ± 1.4 
*Mean ±SD or Percent (frequency). 
†
During the initial treatment phase. 
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Table 4.4. Quality Outcomes at Baseline, Follow-Up, and Both Baseline and Follow-Up (N = 190) 
 
ADA and APA Guideline Baseline  Follow-Up  Baseline & Follow-Up  
 % (n) % (n) % (n) 
Quality Outcomes - Biologic 5.3 (10) 1.6 (3) > 1.0 (1) 
Weight (BMI) 64.2 (122) 63.2 (120) 43.2 (82) 
Waist Circumference* --- --- --- 
Blood Pressure 62.1 (118) 61.6 (117) 38.9 (74) 
Fasting Plasma Glucose (A1c) 27.9 (53) 13.2 (25) 2.1(4) 
Fasting Lipid Profile 8.4 (16) 9.5 (18) 1.1 (2) 
Quality Outcome - History of CVD
†
 34.7 (66) - - 
 Note: Data values in the columns are percent (frequency). 
*Not measured. 
†Baseline only measure. 
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was 45 kg/m
 2
. At baseline and follow-up, of the 119 and 117 patients that had a blood 
pressure measurement, only 12% had an elevated reading. Rates of glycemic 
measurement were lower at baseline (n = 75) and follow-up (n = 39), as were rates of 
elevated measurements at baseline (16%) and follow-up (13.6%). Cholesterol 
measurements at baseline (n = 21) and follow-up (n = 20) were even lower; however, 
elevated readings were high at baseline (61.9%) and follow-up (65.0%). Lipid profile 
measurements were also low at baseline (n = 20) and follow-up (n = 18); however, of the 
measurements, high low-density lipoprotein and triglycerides at baseline (62.5% and 
37.5%) and follow-up (33.3% and 55.6%) were also found to be elevated.  
 
 
Characteristics Associated with Provision of Quality  
 
The final research question asked: What delivery system characteristics are 
associated with receiving cardiometabolic screening at a) baseline, b) follow-up, c) both 
baseline and follow-up? 
 
Simultaneous multiple linear regressions were used to address each of the three 
subcomponents of this research question. The following patient characteristics were not 
included in the correlation matrix or multiple linear regression models due to a lack of 
variation: ethnicity, language best served, marital status, employment status, insurance 
coverage, and federal poverty level. Prior to conducting parametric measures of 
association (Pearson correlations, multiple linear regression) for the remaining candidate 
variables, the skewed continuous age variable was transformed via the square root. This 
new distribution met assumptions. Bivariate correlations among all of the candidate 
variables did not reveal any problems with collinearity, nor did multicollinearity 
diagnostic statistics within each of the simultaneous regression analyses. 
 
 Associations among the patient characteristics are summarized in Table 4.5. Of 
the eight statistically significant correlations, associations were observed of race with 
language spoken (r = .26) and with presence of a mood disorder (r = .18). The 
interpretations suggest that non-white patients were more likely to speak English and 
more likely to have a mood disorder.  Male patients were more likely than females to be a 
current smoker (r = .15) and less likely to have a mood disorder (r = -.19). In addition, 
having a clinic PCP was associated with lower likelihood of having a secondary SUD 
(r = -.17) and an increased likelihood of having a CMI (r = .17).  
 
Associations among the provider characteristics are summarized in Table 4.6. Of 
the three statistically significant correlations, associations were observed of being a 
novice in practice (r = .75) and novice at the clinic (r = 1.0) and MSN education. Being a 
novice in practice and novice at the clinic were also associated (r = .75). 
 
Associations among the visit characteristics are summarized in Table 4.7. Of the 
four statistically significant correlations, associations were observed of being a walk-in at 
baseline and follow-up with walk-in at baseline (r = .48.) and walk-in at follow-up 
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Table 4.5. Associations among Patient Characteristics (N = 190) 
 
Patient 
Characteristic  
Age Male White English Smoker PCP Mood SUD CMI AA 
 Age           
Pearson Correlation - -.024 .024 -.002 -.003 .084 .095 .107 .144* -.089 
Sig.  .741 .746 .982 .964 .250 .190 .143 .048 .220 
Male Gender           
Pearson Correlation - - .013 .024 .154* -.012 -.191* -.042 .093 -.058 
Sig.   .863 .742 .034 .865 .008 .566 .566 .426 
White Race - -         
Pearson Correlation    -.25* .142 .049 -.175* -.031 -.071 .135 
Sig.    < .001 .051 .502 .015 .670 .333 .064 
English Speaking           
Pearson Correlation - - - - .016 -.107 -.015 -.015 .066 -.094 
Sig.     .830 .141 .839 .168 .363 .199 
Current Smoker           
Pearson Correlation - - - - - .144* .077 .065 .010 .004 
Sig.      .048 .291 .376 .893 .960 
Clinic PCP           
Pearson Correlation - - - - - - .096 -.171* .166* .071 
Sig.       .185 .018 .022 .330 
Mood Disorder           
Pearson Correlation - - - - - - - .134 .098 -.035 
Sig.        .064 .178 .627 
Secondary SUD           
Pearson Correlation - - - - - - - - .113 .057 
Sig.         .119 .433 
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Table 4.5. (Continued) 
 
Patient 
Characteristic 
Age Male White English Smoker PCP Mood SUD CMI AA 
Cardiometabolic 
Illness 
          
Pearson Correlation - - - - - - - - - -.134 
Sig.          .065 
Highest Risk AA           
Pearson Correlation - - - - - - - - - - 
Sig.           
*Correlation is statistically significant at the 0.05 level.
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Table 4.6. Associations among Provider Characteristics (N = 8) 
 
Provider Characteristic  MSN 
Education 
NP 
Certification 
Novice in 
Practice 
Novice at 
Clinic 
MSN Education      
Spearman Rho Correlation - .000 .745* 1.000* 
Sig.  1.000 .034 .000 
NP Certification      
Spearman Rho Correlation - - .258 .000 
Sig.   .537 1.000 
Novice in Practice      
Spearman Rho Correlation - - - .745* 
Sig.    .034 
Novice at Clinic      
Spearman Rho Correlation - - - - 
Sig.     
*Correlation is statistically significant at the 0.05 level. 
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Table 4.7. Associations among Visit Characteristics (N = 190) 
 
Visit Characteristic  Walk in 
Visit at 
Baseline 
Walk in 
Visit at 
Follow-Up 
Walk in 
Visit at 
Baseline & 
Follow- Up 
Same 
Provider at 
Baseline & 
Follow- Up 
One or More 
No Show 
Appointment 
Total 
Number 
of Visits 
Walk in Visit at Baseline       
Pearson Correlation - -.033 .482* .017 .044 -.026 
Sig.  .655 .000 .815 .543 .719 
Walk in Visit at Follow-Up       
Pearson Correlation - - .527* -.145* .037 .033 
Sig.   .000 .046 .612 .647 
Walk in Visit at Baseline & 
Follow-Up 
      
Pearson Correlation - - - -.035 -.010 -.034 
Sig.    .632 .892 .645 
Same Provider at Baseline & 
Follow-Up 
      
Pearson Correlation - - - - -.027 -.162* 
Sig.     .711 .025 
One or More No Show 
Appointments 
      
Pearson Correlation - - - - - -.008 
Sig.      .916 
Total Number of Visits       
Pearson Correlation - - - - - - 
Sig.       
*Correlation is statistically significant at the 0.05 level. 
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(r = .53). Patients who had a walk-in at follow-up were less likely to have the same 
provider at baseline and follow up (r = -.15). In addition, having the same provider at 
baseline and follow-up is less likely to be associated with the total number of visits 
(r = -.16). 
 
 Summaries of the unadjusted (r) and adjusted (beta) associations of the patient 
candidate variables with each of the quality outcome variables are presented in Table 4.8. 
At baseline, statistically significant, unadjusted associations were observed between 
being a current smoker (r = .15, p = .041) and having a clinic primary care provider 
(r = .21, p = .003) and the number of quality indicators assessed. At follow-up no 
statistically significant associations were observed. Finally, unadjusted associations 
between having a mood disorder (r = .22; p = .003) were observed for baseline and 
follow-up. None of the three multivariate adjusted models for patient characteristics were 
statistically significant (Baseline: R = .297, p = .076, Adjusted R
2 
= .038; Follow-Up: 
R = .184, p = .792, Adjusted R
2 
= -.020; Baseline & Follow-Up: R = .260, p = .234, 
Adjusted R
2 
= .016). 
Summaries of the unadjusted (r) and adjusted (beta) associations of the visit 
candidate variables with each of the quality outcome variables at follow-up and baseline 
and follow-up are presented in Table 4.9. No statistically significant associations were 
observed. The multivariate adjusted model for visit characteristics was not statistically 
significant (Follow-Up: R = .100, p = .760, Adjusted R
2 
= -.011; Both Baseline and 
Follow- Up: R = .111, p = .312, Adjusted R
2 
= .002). 
 
Summaries of the unadjusted (r) and adjusted (beta) associations of the combined 
delivery system design candidate variables with each of the quality outcome variables are 
presented in Table 4.10. At baseline, statistically significant unadjusted associations were 
observed between being a current smoker (r = .15, p = .041), having a clinic primary care 
provider (r = .21, p = .003) and a walk-in baseline visit (r = .14, p = .048) and the number 
of quality indicators assessed. At follow-up no statistically significant associations were 
observed. At both baseline and follow-up having a mood disorder (r = .22, p = .003) 
found statistically significant unadjusted associations with the number of quality 
indicators assessed. In terms of the adjusted models, the baseline model was statistically 
significant (R = .324, p = .043, Adjusted R
2 
= .049). The single most important and 
statistically significant variable after controlling for all of the other delivery system 
variables was having a clinic primary care provider (beta = .19, p = .011). The adjusted 
follow-up (R = .215, p = .860, Adjusted R
2 
= -.030) and both baseline and follow-up 
(R = .310, p = .105, Adjusted R
2 
= .035) models were not statistically significant. 
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Table 4.8. Patient Characteristics - Multiple Linear Regression 
 
 Baseline  Follow-Up  Baseline & Follow-Up 
Characteristic  r p-value beta p-value  r p-value beta p-value  r p-value beta p-value 
Age -.06 .436 -.07 .323  .06 .400 .07 .381  .08 .263 .08 .278 
Male Gender .07 .329 .06 .406  .05 .509 .05 .480  -.02 .789 .03 .701 
White Race  .02 .748 .02 .833  .01 .980 < .01 .997  -.01 .880 .03 .747 
English 
Speaking 
.03 .676 .06 .400  -.01 .844 -.02 .850  .04 .582 .07 .390 
Current Smoker .15* .041 .11 .158  .09 .185 .09 .223  .05 .465 .30 .691 
Clinic PCP .21* .003 .19* .011  -.05 .516 -.07 .356  .02 .829 .01 .952 
Mood Disorder  .06 .404 .06 .424  .10 .172 .11 .156  .22* .003 .23* .003 
Secondary SUD < .001 1.00 -.06 .435  -.05 .527 -.06 .424  -.02 .841 -.058 .438 
Cardiometabolic    
Illness 
.09 .208 .08 .318  .01 .856 .03 .687  .05 .499 .06 .394 
Highest Risk 
Medication 
.10 .163 .14 .159  .01 .899 .01 .890  .05 .499 .06 .394 
*Correlation or beta is statistically significant at the 0.05 level. 
Baseline:  R = .297, p = .076; R
2
 = .088 (Adjusted R
2
 = .038). 
Follow-Up: R= .184, p = .792; R
2 = 
.034 (Adjusted R
2
 = -.020). 
Baseline & Follow-Up: R = .260, p = .234; R
2
 = .068 (Adjusted R
2
 = .016). 
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Table 4.9. Visit Characteristics - Multiple Linear Regression 
 
 Baseline  Follow-Up  Baseline & Follow-Up 
Characteristic  r p-value beta p-value  r p-value beta p-value  r p-value beta p-value 
WI Baseline --- --- --- ---  --- --- --- ---  --- --- --- --- 
WI Follow-Up 
--- --- --- ---  .03 .676 .02 .799  --- --- --- --- 
WI Baseline & 
Follow-Up 
--- --- --- ---  --- --- --- ---  .09 .218 .07 .366 
Same Provider at 
Baseline & 
Follow-Up  
--- --- --- ---  -.07 .365 -.06 .404  .06 .390 .092 .207 
One or More No 
Show 
Appointments 
--- --- --- ---  .07 .346 .07 .363  --- --- --- --- 
Total Number of 
Visits 
--- --- --- ---  .04 .604 .03 .701  --- --- --- --- 
*Correlation is significant at the 0.05 level. 
Follow-Up: R= .100, p = .760; R
2 = 
.010 (Adjusted R
2
 = -.011). 
Baseline & Follow-Up: R = .111, p = .312; R
2
 = .012 (Adjusted R
2
 = .002). 
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Table 4.10. Delivery System Design - Multiple Linear Regression Models with Candidate Patient and Visit Characteristics 
 
 Baseline  Follow-Up  Baseline & Follow-Up 
Characteristic r p-value beta p-value  r p-value beta p-value  r p-value beta p-value 
Age -.06 .436 -.07 .382  .06 .400 .08 .316  .08 .263 .05 .511 
Male Gender .07 .329 .08 .264  .05 .509 .05 .540  -.02 .798 -.02 .802 
White Race  .02 .748 .05 .949  .00 .980 -.01 .947  -.01 .880 .12 .121 
English Speaking .03 .676 .04 .584  -.01 .844 -.03 .697  .04 .582 .11 .440 
Current Smoker .15 .041 .09 .242  .10 .185 .10 .229  .05 .465 -.14 .072 
Clinic PCP .21 .003 .19 .011  -.05 .516 -.11 .332  .02 .829 .04 .584 
Mood Disorder  .06 .404 .06 .442  .10 .172 .11 .163  .22 .003 .15 .052 
Secondary SUD .00 1.00 -.05 .498  -.05 .527 -.11 .385  -.02 .841 .05 .479 
CMI .09 .208 .08 .265  .01 .856 .02 .788  -.04 .590 -.18 .016 
Highest Risk 
Medication 
.10 .163 .10 .198  .01 .899 .04 .603  .05 .499 .11 .219 
Walk In Baseline .14 .048 .13 .073  --- --- --- ---  --- --- --- --- 
Walk In Follow-
Up 
--- --- --- ---  .03 .676 .01 .917  --- --- --- --- 
Walk In Baseline 
& Follow-Up 
--- --- --- ---  --- --- --- ---  .09 .218 -.01 .900 
Same Provider 
Baseline & 
Follow-Up 
--- --- --- ---  -.07 .365 -.10 .346  .06 .390 .10 .307 
More Than One 
No Show Appt 
--- --- --- ---  .07 .346 .11 .305  --- --- --- --- 
Total Visits  --- --- --- ---  .04 .604 .02 .272  --- --- --- --- 
*Correlation is significant at the 0.05 level. 
Baseline:  R = .324, p = .043; R
2
 = .105 (Adjusted R
2
 = .049). 
Follow-Up: R= .215, p = .860; R
2 = 
.046 (Adjusted R
2
 = -.030).  
Baseline & Follow-Up: R = .310, p = .105; R
2
 = .096 (Adjusted R
2
 = .035).
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CHAPTER 5.    DISCUSSION AND RECOMMENDATIONS 
 
 
This study was undertaken to describe the impact of the delivery system design of 
a community mental health center and the effect on the provision of quality care provided 
to persons with a severe mental illness. The provision of quality of care was defined as 
adherence to American Diabetic Association (ADA), American Psychiatric Association 
(APA), American Association of Clinical Endocrinologists (AACE), and North American 
Association for the Study of Obesity (NAASO) monitoring protocol for persons treated 
on a second or third generation antipsychotic medication, referred to as Atypical 
Antipsychotic (AA) medication.  
 
Firstly, this study investigated the demographic characteristics of the care team, 
which include the patient and provider, and the visits. The second investigation examined 
rates of adherence to the ADA and APA monitoring protocol for persons with a severe 
mental illness, treated on an AA medication. Finally, the study examined associations 
between the patient and visit characteristics with the provision of quality care.  
 
This chapter includes a discussion of study findings and a comparison and 
contrast of the findings with other published studies. First, the elements of the care team 
and visits and provision of quality care for persons with a severe mental illness will be 
discussed. The uniqueness of using the delivery system design element of the Care 
Model, an adapted version of the Chronic Care Model, to evaluate the implementation of 
an evidence based practice monitoring protocol for persons with a severe mental illness 
treated on an AA medication will be discussed. Second, the strengths and limitations of 
this study will be provided, followed by implications for education and practice. Finally, 
this chapter will conclude with a summary and implications for future research.   
 
 
Demographic Characteristics   
 
 
Care Team Patient 
 
The demographic characteristics of the patients in this study are consistent with 
published research, with few exceptions. The study sample included more males (58.4%) 
than females (41.6%), who are younger in age (mean age of 37.1 years), which is 
consistent with the literature. The National Comorbidity Survey found the lifetime risk of 
mental illness, which includes a severe mental illness diagnosis of Major Depression, 
Mania, or Psychosis to be higher in males (48.7%) compared to females (47.3%) 
(Kessler, McGonagle, Zhao, Nelson, Hughes, et al., 1994).  The mean age of patients in 
this study is similar to the findings of the National Comorbidity Survey which found 
higher prevalence of mental illness to be in the age range of 30-44 years (Kessler, 
Berglund, Demler, Jin, Merikangas, et al., 2005).  
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Most patients were not white (53.7%), with African American being the most 
common (26.1%), followed by Somali (15.3%), and Asian (4.7%), as compared to White, 
which comprised a smaller portion of the study (46.3%). These findings are unique when 
compared to the U.S. Census data indicating that 74% of the population is white (U.S. 
Census, 2010). However, the city in the MidWest region, were this study was conducted, 
contains the largest population of Somali outside of Africa (Kroll, Yusuf & Fujiwara, 
2010). While most of the sample spoke English (82.1%), expectedly Somali was the most 
common Non-English language (17.9%).  
 
In this study, more males had mood disorders (38%), compared to females (34%); 
however, males had a thought disorder at a much  higher rate (24%) as compared to 
females (7%). National survey data indicate that life time rates of major depressive 
disorders to be highest in the 35-44 age group, with females having higher rates (23.8%) 
compared to males (14.7%) (Kessler, McGongle, Swartz, Blazer & Nelson, 1993). The 
study findings are inconsistent with national survey data that identified rates of 
Schizophrenia to be non-significantly higher in females than males (Kendle, Gallageher, 
Abelson & Kessler, 1996). 
 
In this study, more blacks had a secondary substance disorder (17%) compared to 
whites (16%). However, more whites (25%) were current smokers compared to blacks 
(16%). Of the nine Asians in this study, only one had a secondary substance use disorder 
and none were current smokers, and most (n = 7) were treated for a mood disorder. 
Studies have noted that few Asians seek mental health treatment (Lee, Martins, Keyes & 
Lee, 2011). While in Asian countries smoke at high rates, however many who come to 
the United States have more education and smoke at lower rates (Fong & Tsuang, 2007).  
 
Consistent with the literature, patients in this study were single, widowed, or 
divorced (90.5%) as compared to those who are married or in a partnership (9.5%). The 
early age of onset of a SMI is a contributing factor to poor psychosocial development and 
which also may lead to low marriage rates. Persons with a mental disorder who receive 
mental health treatment have higher rates of marital disruption or were previously 
married or are single (Kendler, Gallagher, Abelson & Kessler, 1996; Kessler, Berglund, 
Delmer, Jin, Merikangas, et al., 2005; Wang, Lang, Olfson, Pincus, Wells, et al., 2005). 
Additionally, persons who are unemployed, uninsured, or have low income are at higher 
risk for developing a mental disorder or receiving mental health treatment (Kendler, 
Gallagher, Abelson & Kessler, 1996; Kessler, Berglund, Delmer, Jin, Merikangas, et al., 
2005; Wang, Lang, Olfson, Pincus, Wells, et al., 2005).  The findings of this study are 
similar, the majority of patients did not work (88.9%), received public insurance benefits 
(90.0%) and those that reported an income level, most were below the federal poverty 
guidelines (47.4%). 
 
Expectedly, self-reported rates of being a current smoker were high (45.8%). 
While patients self-reported being a current smoker at high rates (45.8%), less than five 
patients have a documented diagnosis of Nicotine Dependence. Findings from this study 
are supported in the literature that report persons with a SMI smoke at very high rates, as 
compared to the general population, and several studies have cited smoking rates in this 
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population to be as high as two to three times the general population (Dixon, Medoff, 
Wohlheiter, DiClemente, Goldberg, et al., 2007).  The finding that few mental health 
providers diagnosis Nicotine Dependence is not uncommon. One study found Nicotine 
Use to be documented in the record up to 88% of the time; however, Nicotine 
Dependence was only documented in 2% of the records (Peterson, Hryshko-Mullen & 
Cortez, 2003).  This finding is an example of the discrepancy between self-report data 
and data documented and / or diagnosed by a mental health provider.  
 
The findings in this study are consistent with other published studies that found 
Mood Disorders, such as Major Depressive Disorder, are more common than Psychotic 
Illness, such as Schizophrenia (Bourdon, Rae, Locke, Narrow & Regier, 1992). In this 
study, Major Depressive Disorder was the most common SMI (38.9%), followed by 
Bipolar I Disorder (24.2%). Fewer patients had Schizophrenia (11.1%) or Schizoaffective 
Disorder (9.5%).  
 
In this study, only 22.2% (n = 47) patients had a documented diagnosis of a 
cardiometabolic illness. This finding is inconsistent with the literature which reports 
persons with a SMI have two or more chronic health conditions, which include: 
hypertension, hyperlipidemia, obesity, or diabetes (Jones, Macias, Barreira, Fisher, 
Hargreaves, et al., 2004; Kilbourne, Post, Nossek, Drill, Cooley, et al., 2008). 
Furthermore, persons with a SMI are diagnosed with diabetes at a younger age, have a 
higher body mass index, and are smokers, compared to those who do not have a SMI 
(Vinogradova, Coupland, Hippisley-Cox, Whyte & Penny, 2010). Of the patients in the 
study who had a body mass index (n = 65), 48% were considered obese with a body mass 
index of 30 kg / m
2
 or greater. Additionally, of the patients that had baseline (n = 21) and 
follow-up (n = 20) cholesterol screening, at baseline 61.9% had an elevated level and at 
follow-up 65% had an elevated level. These findings support difference between finding 
of objective measurement data in the record and actual diagnosis documented. A possible 
rational for this finding is that while psychiatric mental health advanced practice nurses 
are prepared to screen and identify abnormal health findings, some may not document 
physical health findings as the focus of their treatment is on the psychiatric disorder. 
However, holistic client centered care would support screening, documentation and 
referral for abnormal physical health findings.   
 
This study sample is unique in that almost half (47.4%) of the patients did see a 
primary care provider, within the clinic, during the first 16 weeks of treatment. The 
location of the clinic and availability of psychiatric, primary care, and dental services 
might explain the rational for the large number of patients in this study having a primary 
care provider within the clinic. This patient population has both modifiable and 
unmodifiable risk factors for developing obesity and diabetes but few seek primary care 
services and when they do see a primary care provider, more time is used and less 
screening and preventive health care is provided (Daumit, Pratt, Crum, Powe & Ford, 
2002). Unique to this study, patients who had a clinic primary care provider were more 
likely to receive cardiometabolic screening measures at baseline.  
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While high rates of cardiometabolic illnesses, such as obesity, diabetes, 
dyslipidemia, and hypertension have been reported among persons with a SMI (Jones, 
Macias, Barreira, Fisher, Hargreaves et al., 2004; Kilbourne, Post, Nossek, Drill, Cooley, 
et al., 2008), the study findings are not consistent with reported rates of these illnesses. 
Only a small number of patients had a documented diagnosis of hypertension (11.1%); 
however, in the study, of those 118 patients who had a blood pressure taken at baseline, 
19.4% had an elevated blood pressure. And of those 117 patients who had a blood 
pressure at the follow- up visit, 20.5% had an elevated blood pressure. Similarly, in this 
study a small number of patients have a diagnosis of obesity (5.3%); however, 13.2% of 
patients had a body mass index of 30 or above, which meets the criteria for obesity. 
Documented rates of diabetes in this study were low (4.3%), as was hyperlipidemia 
(1.6%); however, rates of elevated glucose at baseline and follow -up were higher at 20% 
and 13.6% respectively. Similarly, at baseline, of the 16 patients who had a lipid profile 
completed, 61.9% had elevated cholesterol, 62.5% had an elevated low density 
lipoprotein and 31.2% had an elevated triglyceride level.  
 
There are severe potential reasons for the differences in diagnosis of obesity, 
hypertension, diabetes, and hyperlimidemia and actual measurement findings that support 
a cardiometabolic illness. First, psychiatric providers are not treating these illness; they 
therefore, may not document the diagnosis. Second, during the initial treatment phase, 
psychiatric acuity is high and therefore, patients are poor self-reporters of co-morbid 
physical health conditions. Finally, a mental health provider may not perceive it within 
their scope of practice to diagnosis or document physical health co-morbidities, based on 
education, training, and experience.  
 
All patients in this study were treated on an atypical antipsychotic medication. 
This study is consistent with three other large claims data base studies that report the 
three most common AA medications prescribed are Quetiapine, Olanzapine, and 
Risperidone (Barnett, VonMuenster, Wehring, Popish, McDonald, et al., 2010; Haupt, 
Rosenblatt, Kim, Baker, Whitehead, et al., 2009; Morrato, Newcomer, Allen & Valuck, 
2008). Clozapine is not considered a first line AA medication due to the need for weekly 
blood draws during the first six months of treatment and monthly thereafter, because of a 
risk for developing agranulocytosis. In this study, a small number of patients were treated 
on this medication (1.6%). Additionally, Paliperidone, was prescribed at low rates 
(1.1%), which might be related to this medication being newest to the market during the 
study period as it was approved in 2006; however, it is found to have lower metabolic 
risks, and therefore may be used more often in the future (Hasnain, Vieweg, Fredrickson, 
Beatty-Brook & Fernandez, et al., 2008). 
 
As a member of the care team, the patient characteristics are an important element 
of the Care Model. Understanding the characteristics of patients with a severe mental 
illness and the interaction with other members of the care team is critical to evaluation of 
quality care outcomes.  
 
 
 76 
Care Team Provider  
 
The care team provider characteristics in this study are unique related to years in 
practice and type of American Nurses Credentialing Center certification, when compared 
to the published literature. Published data on the workforce of advanced practice nurses, 
credentialed as psychiatric mental health nurse practitioners (PMHNP) or clinical nurse 
specialists (CNS) note most providers have been in practice for 30 years or more (23.6%) 
followed by 21-25 years (20.6%), with the fewest being in practice 0-5 years (4.1%) 
(Hanrahan, Delaney & Stuart, 2011). In this study of eight providers, three have been in 
practice for five or less years (37.5%) and of those in practice more than five years; two 
have been in practice more than 10 years (25.0%). One would hypothesize that having a 
younger workforce would increase the likelihood that the advanced practice providers 
have a high level of knowledge related to evidence based practices incorporated in 
everyday practice. The majority of this study (75.0%) have worked at the clinic less than 
five years, suggesting they may not be as embedded and knowledgeable about the system 
in which they are providing care, compared to the two who have been in practice at the 
clinic over 10 years (25.0%). Alternatively, the system may not support the 
implementation of evidence based practices.  
 
A recent workforce study indicated that there are 10,001 PMH APRNs who are 
certificated by the American Nurses Credentialing Center (ANCC), most as Adult CNS 
(70.2%) followed by Adult PMHNP (15.0%), very few as Family PMHNP (4.9%) (Drew 
& Delaney, 2009). The same survey found that most PMH APRNs work in public 
community mental health agencies (20.4%).  Of the eight providers, half were 
credentialed as a CNS (50.0%), and only one was credentialed as a Family PMHNP 
(12.5%).  
 
Workforce data on the highest level of education for psychiatric mental health 
advanced practice registered nurses (PMH APRNs) are not currently published. However, 
it can be postulated that most PMH APRNs’ highest level of education is the Master’s 
Degree, given the first clinical doctorate, Doctor of Nursing Practice (DNP) degrees were 
awarded in 2006. Consistent with the hypothesis, the highest level of education in this 
study six providers (75%) highest level of education was at the Master of Nursing 
Science level. 
 
Given the recommendation of the American Academy of Colleges of Nurses 
(AACN) that the entry level of advanced practice nursing be a the doctoral level by 2015, 
one would expect an increase in the number of doctorally prepared providers (AACN, 
2004). This study included two providers (25%) who had a Doctor of Nursing Practice 
(DNP) degree.Advance practice nurses with a DNP are educationally and clinically 
prepared guided by the AACN’s eight essentials for doctorate education (ANCC, 2006). 
The eight DNP essentials identify that nurses prepared with a clinical doctorate practice 
at the highest level using evidence based practices in complex organizational systems to 
transform health care through quality improvement efforts and evaluate health outcomes 
and develop new approaches to practice. As expert leaders, DNP PMH APRN’s have the 
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knowledge and skill to translate evidence into practice and have an impact on the 
morbidity and mortality of persons with a severe mental illness. 
 
The characteristics of the provider are an important consideration when using the 
Care Model to guide changes within the delivery system of a community mental health 
center. Using the Care Model to develop an integrated care system, the care team can be 
expanded to include nurses who room patients, a primary care provider and case manager 
or care coordinator. Evaluation of the care team and understanding the role of each care 
team member will inform the workforce and guide the evaluation of quality outcomes, 
with the goal of providing client-centered, evidenced based and safe, timely and efficient, 
and coordinated care.  
 
 
Visit Characteristics  
 
Persons with a SMI have no-show rates twice that of other medical specialties; 
about 50% who miss an appointment fall out of treatment (Mitchell & Selmes, 2007). 
Failing an initial psychiatric appointment occurs at rates of about 36%, and follow- up 
fail rates are about 40% (Killaspy, Banerjee, King & Lloyd, 2000). Walk in psychiatric 
appointments are less common; however, they are a way to provide a service when the 
patient is in need. Consistent with the literature, many patients (45.3%) in this study had 
one or more no shows during the first 16 weeks of treatment. Walk in rates among this 
study sample for the initial appointment, baseline appointment were 38.9%.  
  
In contrast, guidelines have been developed on visit frequencies and monitoring 
parameters for chronic physical health conditions, such as congestive heart failure and 
diabetes. Patients who present for few visits related to the treatment of diabetes or present 
for more frequent lower-priority physical health conditions have been found to receive 
care below the diabetes standard (Fenton, VonKorff, Lin, Ciechanowski, & Young, 
2006). Similar findings relate to persons with congestive heart failure. Congestive heart 
failure patients who are followed as an outpatient per the guidelines, followed by family 
practice and specialty care, have improved outcomes (Ezekowitz, vanWalraven, 
McAlister, Armstrong, & Kaul, 2005).  
 
Of interest is the lack of recommended standards of visit frequency for persons 
with a severe mental illness. Revisit intervals have been shown to be understudied and 
impacted by the following patient characteristics: physiological measures, provider 
perception of disease, patient compliance, and co-morbidities (Desalvo, Block, Muntner, 
& Merrill, 2003). However, these authors note the importance of revisit intervals as they 
impact both patient access to care, when patients are scheduled too frequently and other 
patients cannot schedule, and if patients are scheduled infrequently, quality suffers.  
 
 Persons with a SMI are treated for a chronic mental illness and the frequency of 
visits is dependent on the severity of the illness and those who miss appointments have 
higher functional impairments and are in greater need (Centorrio, Hernan, Drago-
Ferrante, Rendall, & Apicella, et al., 2001; Killaspy, Banerjee, King & Lloyd, 2000; 
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Zivin, Pfeiffer, McCammon, Kavanagh, Walter, et al., 2009). In this study, during the 
first 16 weeks of treatment, the mean number of visits was 3.7, with the range being 2-12 
visits and about one third (36.3%) of the patients were treated by the same provider, 
during the first 16 weeks of treatment. Development of guidelines on visit frequencies, 
including RVI could help prevent delayed treatment or prolonged treatment, both of 
which can impact quality outcomes. As part of the Care Model, the visit frequency is an 
important characteristic to consider and a better understanding of visit pattern can guide 
development of innovative care delivery models within an integrated care system.   
 
 
Provision of Quality Care and Quality Outcomes  
 
The study findings indicate that screening rates, following the American Diabetic 
Association (ADA), American Psychiatric Association (APA), American Association of 
Clinical Endocrinologists (AACE), and North American Association for the Study of 
Obesity (NAASO) monitoring protocol for persons treated on a second generation 
antipsychotic (SGA) medication are dismal. Of the 190 in this study no patient had the 
full provision of care, per the ADA and APA monitoring protocol. Excluding history of 
personal and family history of cardiovascular disease, only one patient had the full 
provision of care at baseline and follow- up. Full provision of care is defined as all 
biological screening measures, which include weight or body mass index, blood pressure, 
fasting glucose or hemoglobin A1c, and fasting lipid profile. Following the biological 
measures of the protocol, 5.3% of the study had full provision of quality at baseline and 
1.6% had full provision at follow-up.  
 
In this study the abysmal rates of adherence to the provision of quality, defined as 
rates of full screening per the ADA and APA monitoring protocol may have a 
multifaceted rational. Firstly, the psychiatric acuity of the patient population can shift the 
clinical priorities to stabilization of the mental illness and then screen for cardiometabolic 
symptoms. Many patients are complex and have a hard time verbalizing needs and 
symptoms which can take away time within a clinical encounter to focus the 
measurements required, per the monitoring protocol. Secondly, electronic alerts are not in 
place to prompt providers to screen, per the protocol. Again, lack of built in supportive 
reminders can limit the provision of quality care defined by providing evidenced based 
care. Finally, one can postulate that the 12 week interval seems brief and therefore, 
providers are screening at baseline but the follow- up screening occurs more than three 
months from the baseline screening measures.  
 
 Evaluation of individual measures within the monitoring protocol were improved 
at baseline, follow- up, and both baseline and follow- up. However, rates of screening 
remain low. For example, having a weight or body mass index measure at baseline or 
follow-up occurred in 62.1% and 61.6% of patients at baseline and follow -up, 
respectively. However, only 43.2% of patients had weight or body mass index at baseline 
and follow-up. The one patient that had the full provision of biological screening 
measures at both baseline and follow-up had a baseline body mass index of 24 kg/m
2
 and 
follow-up body mass index of 29 kg/m
2.
These findings highlight the importance of 
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screening for secondary and tertiary preventions in a consistent systematic manner. Given 
that weight and body mass index are inexpensive measures, screening rates should be 
much higher. Additionally, body mass index has been found to be an indicator of 
cardiovascular disease event risk, and is recommended to be included in a cardiovascular 
risk assessment (deKoning, Merchant, Pogue, & Anand, 2007).  
 
Similarly, 62.1% of patients had blood pressure measure at baseline and 61.6% 
had the measure at follow-up, but only 38.9% had the measure at baseline and follow-up. 
Similar to the results of this study, a study conducted looking at screening rates across 
inpatient, outpatient, and in a metabolic clinic found that waist circumference was never 
measured and blood pressure and weight were most commonly measured in the 
outpatient setting, while blood glucose and lipids were rarely measured (Batscha, 
Schneiderhan, Kataria, Rosen & Marvin, 2010).  
 
Evaluation of glycemic measures at baseline were 27.9%, 13.2% at follow-up and 
only 2.1% at baseline and follow-up. Rates of lipid monitoring were even lower, 8.4% at 
baseline, 9.5% at follow-up, and 1.1% at baseline and follow-up. Similar to these 
findings, a large claims data study found that post guideline rates of monitoring lipids and 
glucose at baseline were 23% and 11% and at 12 weeks were 18% and 9% respectively 
(Haupt, Rosenblatt, Kim, Baker, Whitehead, et al., 2009). Consistently claims studies 
have found low rates of glucose and lipid monitoring and adherence to ADA and APA 
guidelines, and recommend interventions to increase screening rates (Barnett, 
VonMuenster, Wehring, Popish & McDonald, et al., 2010; Haupt, Rosenblatt, Kim, 
Baker, Whitehead, et al., 2009; Morrato, Newcomer, Kamat, Baser, Harnett, et al., 2009; 
Morrato, Newcomer, Allen & Valuck, 2008; Morrato, Cuffel, Newcomer, Lombardo, 
Karmat, et al., 2007; Motsinger, Slack, Weaver & Reed, 2006; Shi, Ascher-Svanum, 
Chiang, Zhao, Fonseca, et al., 2009). 
 
The findings of this study are consistent with a meta-analysis that found pre-
guideline screening and monitoring of blood pressure, glycemic measures, and lipid 
measures are suboptimal, weight monitoring is inadequate, and post-guideline studies 
have insufficient data to make an assessment (Mitchell, Vancamfort, Correll & DeHert, 
2012). Another challenge relates to the types of studies conducted and data collected. Of 
the 18 studies on metabolic monitoring, which were conducted in the United States, 10 
are from claims data, six are from the Veterans Administration system, and only two are 
chart of case note review, one of which was with a Hispanic population (Mitchell et al., 
2012). It is difficult to compare full provision of quality care, defined as adherence to the 
ADA and APA monitoring protocol, because most studies on metabolic monitoring used 
claims data. Claims and administrative data were created for billing purposes (Roth, Lim, 
Pevnick, Asch & McGlynn, 2009); therefore, assessment of non-billable measures, such 
as weight, body mass index, blood pressure, or waist circumference cannot be assessed. 
 
The need to assess the validity of claims data is warranted, if data will drive care, 
because clinical data has the ability to evaluate quality outcomes and generate new 
knowledge (Tang, Ralston, Arrigotti, Qureshi & Graham, 2007). Electronic medical 
records were created to capture clinical data, not intended for research, claims data and 
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administrative data were created for billing purposes and lack the quality of clinical 
information, therefore, when extracted is less precise when compared to manual 
extraction (Roth, Lim, Pevnick, Asch & McGlynn, 2009). Quality performance rates are 
known to differ when looking at administrative data, clinical data, or a combined 
approach to data collection. Claims data only and combined collection methods have 
been found to differ by about 10% on specific quality measures (Kmetik, Chung & Sims, 
2007). 
 
In comparison, studies within the Veterans Administration (VA) system have 
higher screening rates. While the study inclusion period is longer in several VA studies, 
the VA is known to have transformed care in the 1990’s by shifting the focus of care 
from outcomes to process and evaluation of measures of quality (Jha, Perlin, Kizer, & 
Dudley, 2003). In addition, the VA system, the largest integrated delivery system in the 
United States, has an electronic health record that allows for automatic queries about 
quality and has registry data, which has the ability to influence provider behavior and has 
improved diabetes care for veterans (Kupersmith, Francis, Kerr, Krein, Pogach, et al., 
2007). The use of electronic medical record data to evaluate performance measures is 
also a rational for the VA systems higher screening rates.  
 
One study in the VA population evaluated rates of screening over 180 days (Shi, 
Ascher-Svanum, Chiang, Zhao, Fonseca, et al., 2009) and the other over one year 
(Khatana, Kane, Taveria, Bauer & Wu, 2011). Both studies did not look at full adherence 
to ADA and APA guidelines, rather at the number of metabolic monitoring measures that 
were completed, which include the same measurements in the ADA and APA guideline. 
Of the Veterans who had one mental health visit in a year, and had complete metabolic 
monitoring (body mass index, blood pressure, blood glucose and lipids), rates were as 
high as 58% for persons with Bipolar Disorder or as low as 15.4% for persons with 
Schizophrenia (Khatana, Kane, Taveria, Bauer & Wu, 2011). In comparison, other 
authors found baseline rates of metabolic screening to be as high as 76% for persons with 
Schizophrenia (Shi, Ascher-Svanum, Chiang, Zhao, Fonseca, et al., 2009). These authors 
note that VA populations tend to be older than Medicaid patients and older patients tend 
to be screened at higher rates. In contrast, this study was younger with a median age of 
35.0 years, but did have more men (n = 111, 58.4%), similar to the VA system; however, 
biological screening rates within the first 16 weeks of treatment were completed on only 
14 patients. A study of patients with schizophrenia in the VA system age 50 old older, 
found rates of screening to be no more than 40%, noting “it would take 40 years to 
achieve 100% monitoring” (pg. 893), following the ADA and APA guidelines (Copeland, 
Parchman, Zeber, Lawrence, Downs, et al., 2010). Overall, screening rates in the VA are 
higher but not optimal; however, health systems can learn from the VA system, a leader 
in using an electronic medical record to evaluate quality performance measures and 
process outcomes to transform care.  
 
In this study evaluations of associations between Patient, Visits, and Quality 
Outcomes did not identify many statistically significant results. However, the adjusted 
model at baseline was statistically significant (R = .324, p = .043, Adjusted R2 = .049). 
The single most important and statistically significant variable for all the other delivery 
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system variables was having a clinic primary care provider (beta = .10, p = .011). At 
baseline, being a current smoker, having a clinic primary care provider, and having a 
same provider at baseline and follow-up were associated with the number of quality 
outcomes. In this study, 47.4% of patients had a clinic primary care provider, and 
supported in the literature, patients with a primary care provider had higher screening 
rates (Haupt, Rosenblatt, Kim, Baker, Whitehead, Newcomer, 2009; Shi, Ascher-
Svanum, Chiang, Zhao, Fonseca, et al., 2009). At follow-up no associations were found 
and at both baseline and follow-up an association was found with having a mood 
disorder; however, this is not cited in the literature.  
 
The low rates of full provision of quality, ADA and APA monitoring protocol in 
addition to low rates of individual screening measures is multifocal. Within the Care 
Model, the care team and visits have an important interaction which can lead to improved 
quality care. For example, lack of continuity between a patient and provider can prevent 
implementation of a treatment plan as each new provider is “reacting” to the patient’s 
need, rather than proactively planning care. In addition, how the patient “visits” the clinic 
has an impact on the provision of quality. A lack of defined roles among the care team 
can also lead to poor quality care due to possible assumptions about who is responsible 
for completing each screening measure and when. The Care Model element, the delivery 
system design allows for re-design of care delivery to develop innovative ways the care 
team and visits impact the provision of quality. Adding additional elements of the Care 
Model, such as self-management support, decision support, and clinical information 
systems can guide improved systems that provide quality care.  
 
 
Strengths and Limitations 
 
 
Strengths 
 
A fundamental strength of the study was the use of an adapted version of the 
Chronic Care Model, the Care Model. The retrospective cross sectional design was also a 
key strength to the study. This study provides a description of the delivery system design 
of the Care Model, care team, and provider characteristics of persons with a serious 
mental illness, treated in a community mental health center.  
 
The Care Model was used to guide the development of the study framework. 
Many studies designed to evaluate and improve the provision of quality care, guided by 
the Chronic Care Model, for persons with other chronic physical health conditions, such 
as diabetes have been effective (Nutting, Dickinson, Dickinson, Nelson & King et al., 
2007; Piatt, Orchard, Emerson, Simmons, & Songer et al;  2006). Additionally, the 
Chronic Care Model has been effective in increasing the adherence to evidence based 
standards, specifically monitoring lipid and glycosylated A1c levels (Siminerio, Piatt & 
Zgibor, 2005). The novel conceptualization of the Care Model and the application to 
persons with a serious mental illness, which is a chronic condition, who have muli-
morbid physical health conditions, such as diabetes is strength to this study. Additionally, 
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the care team and visit variables are present in many community mental health centers; 
therefore, this increases the generalizability of the study framework. 
 
The study used a retrospective cross sectional design. Retrospective cross 
sectional designs are useful in providing a description of variables, patterns of 
distributions and explaining associations to define the clinical characteristics using an 
inexpensive method (Newman, Browner, Cummings, & Hulley, 2001). All candidate 
variables were carefully evaluated for statistical rigor and clinical significance. The 
statistical methods used to describe the study sample and test for associations between the 
candidate variables and quality outcome measures were completed to allow for reliability 
in future studies. Overall, there was a fit between the study design, theoretical 
framework, and research questions. 
 
 
Limitations 
 
Study limitations relate to the methodological issues related to using 
retrospective, clinical data that combined manual extraction and extraction from data 
queries. First, study limitations are related to the use of clinical data that are not intended 
for research. Second, the data used for this study already existed; therefore, the design 
could not control for the completeness, accuracy, and documentation of study data 
values. Third, the use of raw data required that many study variables be transformed and 
re-coded into dummy dichotomous variables, limiting the statistical power when 
compared to studies that use continuous variables. Also, some predictor values could not 
be included in the study because they were not available in the electronic health record or 
from administrative data. 
 
Additionally, treating all persons new to the system as newly prescribed AA 
medications is a limitation. The inclusion criteria did not identify patients who were AA 
naïve from patients who were continuing treatment. Finally, dismal rate of provision of 
quality defined by screening rates, following the American Diabetic Association (ADA), 
American Psychiatric Association (APA), American Association of Clinical 
Endocrinologists (AACE), and North American Association for the Study of Obesity 
(NAASO) monitoring protocol limited the analysis to associations between candidate 
variables and quality outcomes rather than the development of a prediction model. 
 
 
Implications 
 
 
Nursing Education 
 
Psychiatric services provided to persons with serious mental illness (SMI), in 
rural areas or in urban areas with high ethnically diverse populations, who have lower 
educational levels and have lower socioeconomic status, are often delivered by Advanced 
Practice Nurses (APNs) who are certified as a Psychiatric Mental Health Nurse 
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Practitioner (PMHNP) or Clinical Nurse Specialist (CNS). The findings from this study 
highlight the importance of educating APNs about evidence based practice and guidelines 
for specific patient populations. The data on the alarming premature morbidity and 
mortality of this patient population, due to preventable and treatable co-morbid physical 
health conditions, underscores the need for psychiatric APNs to be skilled in screening, 
detecting, and referring patients with a SMI for treatment and having ongoing dialog with 
primary care providers. 
 
Education of psychiatric APNs should include care team clinical teaching and 
management of complex patients. Without instilling the importance of care teams and 
collaborative care, among health care disciplines, care will remain fragmented. 
Educational programs need to include clinical experiences for psychiatric APNs that 
allow for the interaction of multidisciplinary care teams with a focus on how patients and 
providers interact within health systems.  
 
In addition to care teams, psychiatric APN programs should include the 
importance of documentation of accurate health data and assisting students to think about 
clinical data as a rich source of information to inform care and evaluate the provision of 
quality and to be used for research purposes. The American Association of College of 
Nursing Position Statement recommends entry into advanced practice nursing be at the 
doctorate level by 2015, with the rational being the need to prepare providers to work in 
complex health systems treating sicker patient populations (AACN, 2004). The push to 
prepare APNs at the doctorate level highlights that the discipline of nursing has a 
proactive vision to prepare APNs with knowledge and skill to provide quality care within 
complex, fragmented systems and have the knowledge and skills to transform care. 
Nursing educational programs have psychiatric APN students in programs that include an 
increase in clinical hours, which will enables students to learn about and evaluate clinical 
experiences and clinical outcomes with the goal of improving the provision of quality 
care. 
 
Finally, nursing educational programs must educate students about pre-existing 
large data sets that can be accessed to learn about specific patient populations and 
diseases and current national research projects. For example, the Behavioral Risk Factor 
Surveillance System (BRFSS) managed by the Centers for Disease Control (CDC). The 
BRFSS is the largest telephone survey that collects data on health risks, behaviors, and 
practices (CDC, 2012). Understanding how to access large health databases, the data 
collected will help psychiatric APN practice leaders match clinical data to current data to 
compare outcomes and track quality improvement initiatives. Another initiative by the 
Substance Abuse and Mental Health Services Administration (SAMHSA) national 
wellness campaign identified eight domains of wellness, with the goal of addressing the 
morbidity and mortality for persons with a serious mental illness. For example in the state 
of Minnesota, the 10X10 initiative was developed to raise awareness in the state that 
persons with a serious mental illness die 27 years prematurely, compared to matched 
cohorts (Trangle, Mager, Goering & Christensen, 2010). The program is designed to 
assist SMI patients in getting physical health care, with the goal of reducing mortality by 
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10 or more years in 10 years. Educating providers about national and state funded 
initiatives raises awareness of health priorities and provides access to resources.  
 
Practice  
 
The current study findings highlight the critical need to increase the provision of 
evidence based practices into everyday clinical practice. Dismal screening rates identify 
an opportunity to educate providers about current standards of care and the need for 
collaborative efforts to move toward the integration of physical and mental health care, 
especially for those patients with a SMI.  
 
Psychiatric providers can re-examine the importance of assessing not only the 
mental health status but also the physical health status, at the first visit, of all patients 
with a SMI. Because psychiatric providers are prescribing high risk medications, which 
help the psychiatric disorder but may create new physical health co-morbidities or worsen 
pre-existing physical health co-morbidities, it is the responsibility of that prescriber to 
screen and monitor this high risk population and collaborate with primary care when a 
referral is indicated. The need to monitor for medication side effects, in the case of AA 
and the risk of metabolic side effects is the responsibility of the prescribing provider 
(Hasnain, Vieweg, Fredrickson, Beatty-Brooks & Fernandez, et al., 2008). However, 
taking a collaborative approach and educating primary care providers about monitoring 
and screening guidelines can create a synergistic opportunity to improve the provision of 
quality care.  
 
This study highlights the uniqueness of how persons with a SMI interact with 
health systems and provides an opportunity for providers to re-think how best to deliver 
care to patients who present when a problem exists, rather than proactively to prevent an 
acute problem from developing. Incorporation of evidence based practices into each visit, 
which might not be a planned interaction, is a challenge for all providers. However, 
everyday practice should include the identification of the physical health status of the 
patient with a SMI, at the first visit, and comprehensively evaluate health promotion and 
risk reduction screening and interventions including smoking cessation, preventative 
health interventions such as flu shot / TB test, etc. Collaborative efforts with primary care 
and communication about patient health needs are the first steps in combining practice 
based evidence with evidence based practice with the goal of improving health of this 
high risk population.  
 
The next step could be to more aggressively look at successful pay for 
performance programs in general medical services. While pay for performance programs 
exist in behavioral health, few providers opt into these programs (Pelonero & Johnson, 
2007). The development of Accountable Care Organizations (ACOs) and identification of 
core measures for diabetes care is a model that could be used to develop core measures 
for SMI care. The ability to develop transparent and collaborative processes as core 
measurements is critical (Pelonero & Johnson). It is important to be consistent with the 
Institute of Medicine’s aims, and address core quality measures. Systems that embrace 
and support the development and monitoring of core measures that adopt prospective 
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longitudinal quality initiatives (Bremer, Scholle, Keyser, & Houtsinger, 2008) will add to 
available data to set benchmarks for SMI care. An example is the MN DIAMOND 
project which evaluates depression treatment in primary care. Key to pay for performance 
models is the evaluation of measure and outcome (Bremer et al, 2008.). 
 
 
Conclusion and Recommendations for Further Research 
 
The Care Model, an adapted version of the Chronic Care Model, is a useful 
theoretical framework to guide improving provision of quality care provided to patients 
with a SMI. The need to match evidence based practices with real world clinical practice 
is critical. The evidence is clear, persons with a SMI have both modifiable and un-
modifiable risk factors for the development of cardiometabolic illnesses; however, rates 
of screening have not improved. SMI patients are unique in how they interact with the 
health care system. Therefore, as a first step, the system needs to be a planned and 
prepared “responsive” system that supports the provision of quality care, when the patient 
presents to receive care.  
 
A mixed methods study would be useful to understand more about provider 
behavior, who is doing what, when and why along with understanding more about how 
patients with a severe mental illness interact with the health system. A qualitative study 
could increase the understanding about the lived experience of a person with a severe 
mental illness and how this population interacts with the health system. Findings could 
provide date about behaviors between visits, and both facilitators and barriers to seeking 
mental and physical health care. High walk in rates suggest that health systems need to 
provide care when the patient presents for a service and the care needs to respond to the 
need and provide preventive screening and care. The high walk in rate found in this study 
also suggests that provider behavior might be influenced by how patients with a severe 
mental illness interact with the health system. Qualitative study findings about provider 
responses to working with a population with a high no show and walk in rate can help 
design a care model to guide providers in providing quality care in a prepared 
“responsive” system when patients present for care.    
 
Based on the current evidence and present findings, the next step is to design an 
intervention study. Developing an intervention study that uses the Care Model and 
includes the delivery system design, and adds additional elements such as the health 
system organization, decision support, self-management support, and clinical information 
systems has the ability to improve the provision of quality care. For example, providing 
patients with tools to make health decisions between visits by adding the element of self-
management support will lead to more informed and empowered patients. The element of 
clinical information system can address increasing accessibility to evidence based 
standards at the point of care, when the provider is making clinical decisions. Prior to the 
clinical decision making, the clinical information system element can aid in pre-visit 
decision making through the development of patient a registry to guide outcome 
evaluation at the individual provider level and as a cohort. 
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Integrated care teams who work with SMI patients at high risk for developing 
cardiometabolic illnesses, or who already have a cardiometabolic illness guided by the 
Care Model is an innovative design to generate new evidence on an integrated care 
model. In addition, a future prospective intervention study would assist in understanding 
who is ordering the test and why the test is ordered (Morrato, Newcomer, Allen & 
Valuck, 2008), what is done with the result, and whether outcomes improve with increase 
ordering of screening tests (Kilbourne, Post, Bauer, Zeber, Copeland, et al., 2007).  
 
The ability to communicate with the primary care provider is imperative for 
screening and early detection of metabolic side effects, as patients have a limited capacity 
to advocate and care for themselves (Hasnain, Vieweg, Fredrickson, Beatty-Brooks & 
Fernandez, et al., 2008).  Furthermore, if a patient is prescribed a high risk medication, 
AA and the prescriber is not effectively monitoring the patient, the primary care provider 
should talk with the psychiatric prescriber. The integrated model would allow for 
identification of abnormalities, and a collaborative handover to the primary care provider 
for further monitoring and management.  
 
Conceptualizing the chronic illnesses unique to this population and developing 
targeted collaborative initiatives can assist in providing integrative care. Several studies 
have indicated that integrated care models would increase screening rates (DeHert, 
Cohen, Bobes, Cetkovich-Bakmas, Leucht, et al, 2011; Khatana, Kane, Taveria, Bauer & 
Wu, 2011; Mithcell, Delaffon, Vancampfort, Correll & DeHert, 2012; Motsinger, Slack, 
Weaver & Reed, 2006). An example of an integrated care model is the four quadrant 
model (Collins, Hewson, Munger, & Wade, 2010). The four quadrant model is useful to 
identify patients from low behavioral health and low physical health needs to those with 
both high behavioral health and physical health needs. Using registries within an 
integrated clinic can help target the highest risk population and develop targeted mental 
and physical health interventions provided by interdisciplinary care teams.  
Findings from additional studies can help identify what data needs to be matched 
with which provider, with the goal of delivering high quality care. Future studies can 
address challenges of using real clinical data to study outcomes and identify the 
infrastructure needed to support this type of research involving clinical data, given the 
discrepancies between clinical and administrative data (Kmetik, Chung & Sims, 2007; 
Roth, Lim, Pevnick, Asch & McGlynn, 2009). The importance of matching the evidence 
with care, in a model that allows a seamless flow, is imperative to the provision of quality 
care. While it is true that psychiatric care develops out of the relationship (Williams & 
Garner, 2002), and many psychiatric patients are seen in the community, which excludes 
this patient population from randomized clinical trials (Hannes, Pieters, Goedhuys & 
Aergeerts, 2010), mental health providers cannot ignore the need for treatment of 
multimorbid physical health conditions. Data has the ability to drive care and lead to 
highly efficient, effective systems that deliver quality care consistent with the Institute of 
Medicine’s quality underpinnings: patient centered, timely and efficient, evidence based 
and safe, and coordinated (IOM, 2001). Translational research has the ability to bridge 
the quality chasm gap and decrease morbidity and mortality for persons with a SMI. 
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APPENDIX B.    PROVIDER CONSENT FORM 
 
 
      The impact of the delivery system design on 
quality outcomes for patients with severe mental illness in a community 
mental health center: Advanced Practice Registered Nurse Provider 
Survey Consent Form 
 
This brief survey is part of a research study to examine the impact of the delivery system 
design at a community mental health center on quality outcomes for persons with a 
severe mental illness who are at high risk for developing cardiometabolic illness. The 
study period is January 1, 2010 to April 22, 2011. Prior to beginning this study, 
institutional review board (IRB) approval from the University of Tennessee Health 
Science Center (UTHSC) and the XXXXX was obtained. 
 
Dawn Marie Vanderhoef is the primary investigator of this retrospective cross-sectional 
study. The identified study variables related to patient, visits and quality outcomes will be 
extracted from the XXXXX electronic health record by the data team. The advanced 
practice registered nurse provider variables are self-reported by you through a brief five-
item multiple choice survey appended to this consent form. Survey questions address:   
 
 Highest Level of Education 
 Active Psychiatric Nursing Certifications Held  
 Non-Psychiatric Nurse Practitioner Certification 
 Years of APRN practice 
 Years of APRN Employment at XXXXX 
 
This brief survey should take no more than 10 minutes of your time to complete. 
 
There are no foreseeable risks related to your participation in this brief survey. Your data 
will remain confidential, as there are no required identifiers. All paper research records 
will be stored in locked file cabinets and will be accessible only to me, the principle 
investigator. All electronic research records will be computer password protected and 
accessible only to me, the principle investigator. You will not be identified in any 
presentations or publications based on the results of this research study.  
 
The benefits to participation in this study are to help develop a better understanding of 
the attributes of the community mental health centers delivery design that can lead to 
improved outcomes and impact the morbidity and mortality of persons with a severe 
mental illness. Participation in this brief survey is voluntary and there are no adverse 
affects if you choose not to participate. You may refuse to answer any of the questions, 
though completed surveys are preferred.  
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If you have any questions about this research study you may contact Dawn Marie 
Vanderhoef at XXXXX. You may contact Terrence F. Ackerman, Ph.D., UTHSC IRB 
Chairman at XXXXX or visit the IRB website at 
http://www.uthsc.edu/research/research_compliance/IRB/ 
participant_complaint.php if you have any questions about your rights as a participant in 
this study or your rights as a research subject. 
 
CONSENT OF SUBJECT: 
 
You have read or have had read to you a description of the research study as outlined 
above.  The investigator or his/her representative has explained the study to you and has 
answered all the questions you have at this time.  You knowingly and freely choose to 
participate in the study.  A copy of this consent form will be given to you for your 
records. 
 
 
__________________________________________ ___________ _________ 
Signature of Research Subject    Date  Time 
 
 
Printed Name of Research Subject 
 
__________________________________________      ___________ __________ 
Signature of Person Obtaining Consent  Date  Time 
 
 
Printed Name of Person Obtaining Consent 
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APPENDIX C.    PROVIDER SURVEY 
 
 
      The impact of the delivery system design on 
quality outcomes for patients with severe mental illness in a community 
mental health center: Advance Practice Registered Nurse Provider 
Survey Form 
 
SURVEY QUESTIONS:  Please answer the questions based on your work at XXXXX during 
the study period of January 1, 2010 to April 22, 2011.  
 
1. What is your highest level of education (degree earned)? 
a. Master of Science  
b. Doctor of Nursing Practice 
c. Educational Doctorate 
d. Doctor of Nursing Science  
e. Nursing Doctorate  
f. Doctor of Philosophy 
g. Other (please list) __________________________ 
 
2. What type(s) of American Nurses Credentialing Center (ANCC) certification do you 
hold? Circle all that apply. 
a. Family Psychiatric Mental Health Nurse Practitioner  
b. Adult Psychiatric Mental Health Nurse Practitioner  
c. Child and Adolescent Clinical Nurse Specialist  
d. Adult Clinical Nurse Specialist  
 
3. Are you certified by a National Credentialing Body as a Family Nurse Practitioner, 
Pediatric Nurse Practitioner, Adult Nurse Practitioner or Geriatric Nurse Practitioner? 
a. Yes 
b. No 
 
4. How many years have you practiced as an Advanced Practice Registered Nurse? 
a. Less than 1 year  
b. One to three years 
c. Greater than three years but less than five years  
d. Greater than five years but less than 10 years  
e. Greater than 10 years  
 
5. How many years have you been employed by XXXXX as an Advanced Practice 
Registered Nurse during the study period of January 1, 2010 to April 22, 2011?  
a. Less than 1 year  
b. One to three years  
c. Greater than three years but less than five years  
d. Greater than five years but less than 10 years 
e. Greater than 10 years 
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